

Mario Boccadoro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1499858/publications.pdf>

Version: 2024-02-01

667
papers

36,237
citations

4383

86
h-index

4112

175
g-index

672
all docs

672
docs citations

672
times ranked

19894
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2023, 30, 3-17.	1.4	22
2	Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients. <i>European Journal of Haematology</i> , 2022, 108, 178-189.	1.1	5
3	Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2022, 29, 1-7.	1.4	42
4	Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials. <i>Hematological Oncology</i> , 2022, 40, 704-715.	0.8	6
5	Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. <i>Journal of Clinical Oncology</i> , 2022, 40, 3406-3418.	0.8	115
6	High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 3120-3131.	0.8	29
7	Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies. <i>Haematologica</i> , 2021, 106, 1079-1085.	1.7	12
8	Standardization of ¹⁸ F-FDG PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 116-125.	0.8	85
9	Daratumumab-Based Therapy for IgM Multiple Myeloma With Hyperviscosity Syndrome: A Case Report. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e21-e24.	0.2	2
10	Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2021, 35, 31-44.	3.3	79
11	A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma. <i>Annals of Hematology</i> , 2021, 100, 437-443.	0.8	11
12	Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma. <i>Hematological Oncology</i> , 2021, 39, 293-303.	0.8	6
13	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e105-e118.	5.1	136
14	Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score. <i>Blood Cancer Journal</i> , 2021, 11, 73.	2.8	7
15	Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients. <i>Clinical Cancer Research</i> , 2021, 27, 3695-3703.	3.2	7
16	European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma. <i>Haematologica</i> , 2021, 106, 2054-2065.	1.7	27
17	Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. <i>Annals of Hematology</i> , 2021, 100, 2325-2337.	0.8	21
18	Targeting HIF-1 β Regulatory Pathways as a Strategy to Hamper Tumor-Microenvironment Interactions in CLL. <i>Cancers</i> , 2021, 13, 2883.	1.7	12

#	ARTICLE	IF	CITATIONS
19	Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial. <i>Blood Cancer Journal</i> , 2021, 11, 106.	2.8	31
20	Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network. <i>Cancer</i> , 2021, 127, 3413-3421.	2.0	4
21	Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2021, 137, 3027-3036.	0.6	40
22	Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. <i>Blood</i> , 2021, 137, 3507-3517.	0.6	30
23	Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2021, 22, 801-812.	5.1	162
24	2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. <i>Haematologica</i> , 2021, 106, 2799-2812.	1.7	22
25	Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. <i>Future Oncology</i> , 2021, 17, 2499-2512.	1.1	11
26	Can the dismal prognosis of patients with central nervous system plasma cell neoplasms be improved?. <i>Leukemia Research</i> , 2021, 107, 106592.	0.4	1
27	Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3613-3622.	0.8	25
28	Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy. <i>Advances in Therapy</i> , 2021, 38, 1328-1341.	1.3	2
29	Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. <i>HemaSphere</i> , 2021, 5, e528.	1.2	45
30	Standardization of flow cytometric minimal residual disease assessment in international clinical trials. A feasibility study from the European Myeloma Network. <i>Haematologica</i> , 2021, 106, 1496-1499.	1.7	9
31	The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. <i>Pharmaceuticals</i> , 2021, 14, 20.	1.7	9
32	COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. <i>Lancet Haematology</i> , 2021, 8, e934-e946.	2.2	46
33	OAB-055: Gain and amplification of 1q induce transcriptome deregulation and worsen the outcome of newly diagnosed Multiple Myeloma patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S34.	0.2	2
34	P-065: CyTOF and single cell RNA sequencing reveal altered T cell phenotypes in Multiple Myeloma patients: implications for immunotherapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S74-S75.	0.2	0
35	Prediction of Early Death and Severe Infections during Novel Agent-Based Induction Therapy in Newly-Diagnosed Multiple Myeloma: An Intergroup Analysis from the German Speaking Myeloma Multicenter Group, the Dutch-Belgian Cooperative Trial Group for Hematology Oncology Foundation and the European Myeloma Network. <i>Blood</i> , 2021, 138, 3792-3792.	0.6	0
36	The INSURE Study (INSIGHT MM, LVEA-IXA, REMIX): A Pooled Analysis of Relapsed/Refractory Multiple Myeloma (RRMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice. <i>Blood</i> , 2021, 138, 2701-2701.	0.6	2

#	ARTICLE	IF	CITATIONS
37	Pan-Stakeholder Core Outcome Set (COS) Definition for Selected Hematological Malignancies - Results of the Harmony Alliance. <i>Blood</i> , 2021, 138, 5031-5031.	0.6	0
38	Cost efficiency and effectiveness of biosimilar filgrastim in autologous transplant. <i>Bone Marrow Transplantation</i> , 2021, , .	1.3	0
39	Carfilzomib, Pomalidomide and Dexamethasone (KpD) in Patients with First Progression of Multiple Myeloma Refractory to Bortezomib and Lenalidomide. Final Report of the EMN011/HOVON114 Trial. <i>Blood</i> , 2021, 138, 1664-1664.	0.6	6
40	Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1705-1720.	5.1	120
41	Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial. <i>Blood Cancer Journal</i> , 2021, 11, 197.	2.8	5
42	Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. <i>Haematologica</i> , 2020, 105, 193-200.	1.7	29
43	HIF-1 α is over-expressed in leukemic cells from <i>p53</i> -disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 1042-1054.	1.7	39
44	First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials. <i>Haematologica</i> , 2020, 105, 1074-1080.	1.7	16
45	Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial. <i>Haematologica</i> , 2020, 105, 1937-1947.	1.7	29
46	Should high-risk smouldering multiple myeloma be treated?. <i>Lancet Haematology</i> , the, 2020, 7, e15-e16.	2.2	1
47	Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma. <i>Cancers</i> , 2020, 12, 15.	1.7	39
48	Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation. <i>Annals of Hematology</i> , 2020, 99, 2197-2199.	0.8	5
49	Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. <i>Lancet Haematology</i> , the, 2020, 7, e861-e873.	2.2	34
50	Immunomodulatory and clinical effects of daratumumab in <i>T</i> -cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2020, 191, e28-e32.	1.2	13
51	Diagnostic and Therapeutic Challenges in the Management of Intermediate and Frail Elderly Multiple Myeloma Patients. <i>Cancers</i> , 2020, 12, 3106.	1.7	12
52	Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia. <i>Frontiers in Immunology</i> , 2020, 11, 594556.	2.2	39
53	CLL-220: Modulation of Phenotypic and Functional Features of Immune Cells in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S224-S225.	0.2	0
54	Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8192.	1.8	14

#	ARTICLE	IF	CITATIONS
55	Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study. <i>Blood Cancer Journal</i> , 2020, 10, 58.	2.8	9
56	New drugs in early development for treating multiple myeloma: all that glitters is not gold. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 989-1004.	1.9	4
57	Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing. <i>Clinical Cancer Research</i> , 2020, 26, 4832-4841.	3.2	33
58	Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2020, 9, 2142.	1.0	13
59	Extended half-life rFIX in major surgery—How to improve clinical practice: An intraindividual comparison. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 531-534.	0.2	7
60	Droplet Digital PCR Assay for <i>MYD88</i> ^{L265P} : Clinical Applications in Waldenström Macroglobulinemia. <i>HemaSphere</i> , 2020, 4, e324.	1.2	3
61	Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma. <i>Frontiers in Oncology</i> , 2020, 10, 1.	1.3	156
62	Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs. <i>Cancers</i> , 2020, 12, 282.	1.7	22
63	Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials. <i>Haematologica</i> , 2020, 106, 291-294.	1.7	17
64	Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. <i>Lancet Haematology</i> , 2020, 7, e456-e468.	2.2	244
65	Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. <i>Blood Cancer Journal</i> , 2020, 10, 40.	2.8	15
66	Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). <i>Leukemia</i> , 2020, 34, 2000-2011.	3.3	109
67	Effectiveness and Safety of Ixazomib-Based Therapy in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated Outside the Clinical Trial Setting Via an Early Access Program (EAP) in Europe: Second Interim Analysis of the 'Use Via Early Access to Ixazomib' (UVEA-IXA) Study. <i>Blood</i> , 2020, 136, 42-44.	0.6	4
68	Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study. <i>Blood</i> , 2020, 136, 37-38.	0.6	16
69	Characterization of B-Cell and Plasma Cell Compartment By Eight-Color Multiparameter Flow Cytometry in Patients with Waldenström Macroglobulinemia Prospectively Enrolled in the Fondazione Italiana Linfomi (FIL) BIO-WM Trial. <i>Blood</i> , 2020, 136, 29-30.	0.6	16
70	Biomarkers of Acute Graft-Versus-Host Disease: Surface Antigens and Micro Rnas in Extracellular Vesicles. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S232.	2.0	4
71	Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis. <i>Cancers</i> , 2019, 11, 1735.	1.7	7
72	Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial. <i>Journal of Hematology and Oncology</i> , 2019, 12, 4.	6.9	27

#	ARTICLE	IF	CITATIONS
73	FLAI induction regimen in elderly patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 3339-3340.	0.6	6
74	Expert Panel Consensus Statement for Proper Evaluation of First Relapse in Multiple Myeloma. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 187-196.	1.2	8
75	INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma. <i>Future Oncology</i> , 2019, 15, 1411-1428.	1.1	23
76	Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study. <i>Future Oncology</i> , 2019, 15, 897-907.	1.1	9
77	Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN 503): final results of an open-label, phase 1/2 study. <i>British Journal of Haematology</i> , 2019, 186, e35-e39.	1.2	12
78	Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. <i>Journal of Internal Medicine</i> , 2019, 286, 63-74.	2.7	42
79	Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies. <i>Haematologica</i> , 2019, 104, 1640-1647.	1.7	22
80	Insights on Multiple Myeloma Treatment Strategies. <i>HemaSphere</i> , 2019, 3, e163.	1.2	33
81	Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network. <i>Haematologica</i> , 2019, 104, 2358-2360.	1.7	18
82	A tale of two paradigms: fixed duration vs continuous therapy in routine clinical practice: An INSIGHT MM study analysis of duration of therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e4-e5.	0.2	0
83	Applying Data Warehousing to a Phase III Clinical Trial From the Fondazione Italiana Linfomi Ensures Superior Data Quality and Improved Assessment of Clinical Outcomes. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-15.	1.0	7
84	Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies. <i>Cancers</i> , 2019, 11, 2015.	1.7	26
85	Maintenance Therapy vs Re-treatment at Biochemical Relapse vs Observation in Relapsed/Refractory Multiple Myeloma Patients: Results of a Phase II, Randomized Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e271.	0.2	0
86	Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis. <i>Cancer</i> , 2019, 125, 750-760.	2.0	31
87	Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated same-day (24h), per-guidelines (24-72h), and late (>72h): findings from the MONITOR-GCSF study. <i>Supportive Care in Cancer</i> , 2019, 27, 2301-2312.	0.6	3
88	Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the Tj ETQq0 00rgBT /Overlock 10		
89	Tumor Circulating Plasma Cells Detected By Flow Cytometric Single Platform Method Correlate with Clinical Response to Therapy and Unfavorable Patients' Characteristics. <i>Blood</i> , 2019, 134, 4357-4357.	0.6	3
90	Minimal Residual Disease Evaluation By Multiparameter Flow Cytometry and Next Generation Sequencing in the Forte Trial for Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2019, 134, 4322-4322.	0.6	15

#	ARTICLE	IF	CITATIONS
91	MRD Evaluation By PET/CT According to Deauville Criteria Combined with Multiparameter Flow Cytometry in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients Enrolled in the Phase II Randomized Forte Trial. <i>Blood</i> , 2019, 134, 4321-4321.	0.6	8
92	Integrative Analysis of Baseline Prognostic Features and Achievement of Minimal Residual Disease Negativity As Predictors of Early Relapse in Transplant-Eligible Multiple Myeloma Patients. <i>Blood</i> , 2019, 134, 605-605.	0.6	3
93	Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019, 134, 3031-3031.	0.6	2
94	Predictive Model of Early Relapse in Newly Diagnosed Multiple Myeloma: Analysis from a Pooled Dataset. <i>Blood</i> , 2019, 134, 2130-2130.	0.6	1
95	Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: Analysis of over 3,000 Pts from the Insight MM Global, Prospective, Observational Study. <i>Blood</i> , 2019, 134, 1887-1887.	0.6	12
96	Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study. <i>Blood</i> , 2019, 134, 1845-1845.	0.6	2
97	Negative Selective Pressure Exerted By Maintenance Therapy Promotes the Extinction of Sub-Clones Carrying High-Risk Lesions in Multiple Myeloma. <i>Blood</i> , 2019, 134, 1778-1778.	0.6	1
98	Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: Results from the FORTE trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8002-8002.	0.8	67
99	Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase III study (PERSEUS).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS8055-TPS8055.	0.8	31
100	Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma. <i>Current Medicinal Chemistry</i> , 2019, 26, 5968-5981.	1.2	6
101	Adoptive immunotherapy with CAR modified T cells in cancer current landscape and future perspectives. <i>Frontiers in Bioscience - Landmark</i> , 2019, 24, 1284-1315.	3.0	12
102	Validation and Improvement Opportunities of the Revised International Staging System for Multiple Myeloma: An Analysis on Mature Data from European Clinical Trials within the Harmony Big Data Platform. <i>Blood</i> , 2019, 134, 1773-1773.	0.6	1
103	The Use of Venetoclax for Acute Myeloid Leukemia in a Real-Life Setting: A Multicenter National Experience. <i>Blood</i> , 2019, 134, 5098-5098.	0.6	0
104	Efficacy and Safety of Ixazomib-Dexamethasone, Ixazomib-Cyclophosphamide-Dexamethasone, Ixazomib-Thalidomide-Dexamethasone and Ixazomib-Bendamustine-Dexamethasone for Elderly Newly Diagnosed Multiple Myeloma (NDMM) Patients: Analysis of the Phase II Randomized Unito-EMN10 Study. <i>Blood</i> , 2019, 134, 3195-3195.	0.6	0
105	IgM-Gammopathies Transformed into Aggressive Lymphoma: Incidence, Basal Clinical Features and Outcome of a Registry Based, Spanish Retrospective Series. <i>Blood</i> , 2019, 134, 4011-4011.	0.6	0
106	The Locomotion Study (MMY4001): A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients with Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMiD, and CD38 Monoclonal Antibody Treatment and Documented Disease Progression. <i>Blood</i> , 2019, 134, 5549-5549.	0.6	1
107	Clonal Evolution of Multiple Myeloma in Patients from Diagnosis to First Relapse, Who Were Treated in Subsequent Clinical Trials. <i>Blood</i> , 2019, 134, 1798-1798.	0.6	0
108	Pre-Existing and Treatment-Emergent Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Drugs. <i>Blood</i> , 2019, 134, 3044-3044.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1357-1366.	1.2	8
110	Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study. <i>Leukemia</i> , 2018, 32, 1803-1807.	3.3	39
111	A retrospective study of Râ€DHAP/Ox for early progressing follicular lymphoma. <i>British Journal of Haematology</i> , 2018, 183, 828-831.	1.2	3
112	Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma. <i>Leukemia</i> , 2018, 32, 979-985.	3.3	25
113	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2018, 32, 1542-1560.	3.3	68
114	Promising Role of Extracellular Vesicles as Biomarkers of Acute Graft-vs.-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S196.	2.0	0
115	Highly sensitive <i>MYD88</i> ^{L265P} mutation detection by droplet digital polymerase chain reaction in Waldenström macroglobulinemia. <i>Haematologica</i> , 2018, 103, 1029-1037.	1.7	61
116	Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up. <i>British Journal of Haematology</i> , 2018, 181, 693-695.	1.2	1
117	Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 189-193.	2.0	21
118	Extracellular vesicles as potential biomarkers of acute graft-vs-host disease. <i>Leukemia</i> , 2018, 32, 765-773.	3.3	32
119	From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. <i>Haematologica</i> , 2018, 103, 197-211.	1.7	110
120	Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 91-99.	1.5	17
121	Thrombopoietin receptor agonists in patients with persistent or chronic immune thrombocytopenia. <i>European Journal of Haematology</i> , 2018, 100, 304-307.	1.1	1
122	CD38 as an immunotherapeutic target in multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 1209-1221.	1.4	27
123	Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma. <i>Frontiers in Immunology</i> , 2018, 9, 2749.	2.2	41
124	A prospective observational study to assess clinical decision-making, prognosis, quality of life and satisfaction with care in patients with relapsed/refractory multiple myeloma: the CLARITY study protocol. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 127.	1.0	6
125	Regulation of HIF-1 \pm in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S214.	0.2	0
126	Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 132, 9-16.	2.0	13

#	ARTICLE	IF	CITATIONS
127	European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. <i>Haematologica</i> , 2018, 103, 1772-1784.	1.7	86
128	A Global Treatment Standard in Multiple Myeloma (MM) Remains Elusive Despite Advances in Care over 15 years: First Results from INSIGHT MM, the Largest Global Prospective, Observational MM Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S247-S248.	0.2	1
129	Translocation (14;16) Positive Multiple Myeloma: Clinical Features and Survival Outcomes of a High-risk Population. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S250-S251.	0.2	0
130	A look at treatment strategies for relapsed multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 735-750.	1.1	2
131	Determining treatment intensity in elderly patients with multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 917-930.	1.1	10
132	Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e401-e419.	0.2	61
133	Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). <i>Haematologica</i> , 2018, 103, 1422-1432.	1.7	70
134	European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. <i>Leukemia</i> , 2018, 32, 1883-1898.	3.3	81
135	The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib. <i>British Journal of Haematology</i> , 2018, 182, 701-704.	1.2	22
136	Gentle yet effective combination therapy with novel agents in elderly multiple myeloma patients. <i>British Journal of Haematology</i> , 2018, 182, 165-167.	1.2	0
137	Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 130, 27-35.	2.0	25
138	Maintenance Treatment and Survival in Patients With Myeloma. <i>JAMA Oncology</i> , 2018, 4, 1389.	3.4	67
139	Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 533-540.	0.2	9
140	Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). <i>Leukemia</i> , 2018, 32, 1697-1712.	3.3	83
141	Standardization of 18F-FDG PET/CT According to Deauville Criteria for MRD Evaluation in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Joint Analysis of Two Prospective Randomized Phase III Trials. <i>Blood</i> , 2018, 132, 257-257.	0.6	20
142	Efficacy and Feasibility of Dose/Schedule-Adjusted Rd-R Vs. Continuous Rd in Elderly and Intermediate-Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients: RV-MM-PI-0752 Phase III Randomized Study. <i>Blood</i> , 2018, 132, 305-305.	0.6	30
143	Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM). <i>Blood</i> , 2018, 132, 121-121.	0.6	46
144	Double Vs Single Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Long-Term Follow-up (10-Years) Analysis of Randomized Phase 3 Studies. <i>Blood</i> , 2018, 132, 124-124.	0.6	41

#	ARTICLE	IF	CITATIONS
145	Ixazomib Plus Lenalidomide-Dexamethasone (IRd) in Relapsed/Refractory Multiple Myeloma (MM) Patients (Pts) - Effectiveness in Routine Clinical Practice Is Similar to the Efficacy in the Phase 3 Tourmaline-MM1 Trial: A Pooled Analysis from the Insight MM Observational Study and the Czech Registry of Monoclonal Gammopathies (RMG). <i>Blood</i> , 2018, 132, 1971-1971.	0.6	5
146	Carfilzomib, Pomalidomide and Dexamethasone (Kpd) in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide. the EMN011 Trial. <i>Blood</i> , 2018, 132, 801-801.	0.6	26
147	Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 4412-4412.	0.6	2
148	Updated efficacy data and MRD analysis according to risk status in newly diagnosed myeloma patients treated with carfilzomib + lenalidomide or cyclophosphamide (FORTE trial).. <i>Journal of Clinical Oncology</i> , 2018, 36, 8009-8009.	0.8	2
149	Carfilzomib, bendamustine, and dexamethasone (KBd) in advanced multiple myeloma: The EMN09-trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8019-8019.	0.8	8
150	Impact of baseline renal function on efficacy and safety of daratumumab plus bortezomib-melphalan-prednisone (VMP) in patients (Pts) with newly diagnosed multiple myeloma (NDMM) ineligible for transplantation (ALCYONE).. <i>Journal of Clinical Oncology</i> , 2018, 36, e20024-e20024.	0.8	2
151	Outcome of Soft-Tissue Plasmocytomas in Newly Diagnosed Multiple Myeloma Patients Treated with New Drugs. <i>Blood</i> , 2018, 132, 3235-3235.	0.6	0
152	Once Weekly Versus Twice Weekly Carfilzomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma: A Pooled Analysis of Two Phase 1/2 Studies. <i>Blood</i> , 2018, 132, 1990-1990.	0.6	0
153	Transplant Status Does Not Impact the Selection of Induction Regimens for Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) in the Insight MM Prospective, Observational Study. <i>Blood</i> , 2018, 132, 3289-3289.	0.6	4
154	Long-Term Carfilzomib for High-Risk Patients with Newly Diagnosed Multiple Myeloma: A Pooled Analysis of Two Phase 1/2 Studies. <i>Blood</i> , 2018, 132, 3240-3240.	0.6	0
155	Can pegylated interferon improve the outcome of polycythemia vera patients?. <i>Journal of Hematology and Oncology</i> , 2017, 10, 15.	6.9	15
156	Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study. <i>Supportive Care in Cancer</i> , 2017, 25, 1819-1828.	1.0	20
157	Magic pills: new oral drugs to treat chronic lymphocytic leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 411-425.	0.9	9
158	Bortezomib, melphalan, and prednisone in elderly relapsed/refractory multiple myeloma patients: update of multicenter, open-label Phase 1/2 study. <i>Leukemia and Lymphoma</i> , 2017, 58, 2738-2740.	0.6	1
159	How is patient care for multiple myeloma advancing?. <i>Expert Review of Hematology</i> , 2017, 10, 551-561.	1.0	11
160	Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 75-87.	1.1	1
161	Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma. <i>European Journal of Haematology</i> , 2017, 98, 289-295.	1.1	2
162	Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 471-478.	0.2	34

#	ARTICLE	IF	CITATIONS
163	Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma. <i>Bone Marrow Transplantation</i> , 2017, 52, 1208-1211.	1.3	8
164	Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis. <i>Leukemia</i> , 2017, 31, 1727-1734.	3.3	41
165	Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 388-397.	2.0	72
166	Data quality improvement of a multicenter clinical trial dataset. , 2017, 2017, 1190-1193.		6
167	Novel Immunotherapies for Multiple Myeloma. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 344-357.	1.2	30
168	Updated analysis of CALGB (Alliance) 100104. <i>Lancet Haematology</i> , 2017, 4, e404-e405.	2.2	0
169	Heavy+Light Chain and Free Light Chain Assays at Baseline and During Follow-up in EMN02/HO95 Multiple Myeloma Clinical Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e47.	0.2	0
170	Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Patients: A Multicenter, Open Label Phase 1/2 Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e59.	0.2	2
171	Upfront Tandem Auto-Allo Transplant in Multiple Myeloma: Long-Term Follow-Up and Impact of "New Drugs" at Relapse. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e66-e67.	0.2	0
172	Systemic virotherapy for multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1-13.	1.4	11
173	Melphalan hydrochloride for the treatment of multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1127-1136.	0.9	44
174	Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: Patterns, outcomes, and determinants (MONITOR-GCSF study). <i>Journal of Geriatric Oncology</i> , 2017, 8, 86-95.	0.5	22
175	How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience. <i>British Journal of Haematology</i> , 2017, 176, 669-671.	1.2	9
176	HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data. <i>BMC Bioinformatics</i> , 2017, 18, 516.	1.2	10
177	Impact of Bortezomib- or Lenalidomide-Based Induction Treatment on High Risk Cytogenetic Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Enrolled in the Gimema-MM-03-05 and EMN01 Trials. <i>Blood</i> , 2017, 130, 744-744.	0.6	10
178	Long Term Outcome of Lenalidomide-Dexamethasone (Rd) Vs Melphalan-Lenalidomide-Prednisone (MPR) Vs Cyclophosphamide-Prednisone-Lenalidomide (CPR) As Induction Followed By Lenalidomide-Prednisone (RP) Vs Lenalidomide (R) As Maintenance in a Community-Based Newly Diagnosed Myeloma Population: Updated Analysis of EMN01 Phase III Study. <i>Blood</i> , 2017, 130, 901-901.	0.6	7
179	Carfilzomib-lenalidomide-dexamethasone (KRd) vs carfilzomib-cyclophosphamide-dexamethasone (KCd) induction: Planned interim analysis of the randomized FORTE trial in newly diagnosed multiple myeloma (NDMM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8003-8003.	0.8	13
180	Minimal residual disease (MRD) monitoring by multiparameter flow cytometry (MFC) in newly diagnosed transplant eligible multiple myeloma (MM) patients: Results from the EMN02/HO95 phase 3 trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8011-8011.	0.8	15

#	ARTICLE	IF	CITATIONS
181	Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis. <i>Oncotarget</i> , 2017, 8, 5924-5935.	0.8	33
182	Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia. <i>Oncotarget</i> , 2017, 8, 3274-3288.	0.8	13
183	Emerging drugs and combinations to treat multiple myeloma. <i>Oncotarget</i> , 2017, 8, 60656-60672.	0.8	39
184	Autologous transplant for myeloma: when the old meets the new. <i>Oncotarget</i> , 2017, 8, 90618-90619.	0.8	0
185	Ruxolitinib in steroid refractory graft-vs.-host disease: a case report. <i>Journal of Hematology and Oncology</i> , 2016, 9, 67.	6.9	21
186	Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2016, 127, 1102-1108.	0.6	78
187	Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents. <i>Cytometry Part B - Clinical Cytometry</i> , 2016, 90, 81-90.	0.7	45
188	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. <i>Lancet Oncology</i> , The, 2016, 17, e328-e346.	5.1	1,866
189	Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study). <i>Annals of Oncology</i> , 2016, 27, 2039-2045.	0.6	27
190	Long-term therapy-free remission in a patient with platelet-derived growth factor receptor beta rearranged myeloproliferative neoplasm. <i>American Journal of Hematology</i> , 2016, 91, E353.	2.0	3
191	A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma. <i>Leukemia</i> , 2016, 30, 1320-1326.	3.3	38
192	Role of Chemotherapy and Allografting in the Treatment of Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 96-103.	0.2	1
193	Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT) <i>TJ ETQq1 1 0.784314 rgBT /Ove</i>	0.6	7
194	Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma. <i>Leukemia</i> , 2016, 30, 1211-1214.	3.3	33
195	Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study). <i>Supportive Care in Cancer</i> , 2016, 24, 911-925.	1.0	62
196	A Multicenter, Open Label Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (MM) Patients. <i>Blood</i> , 2016, 128, 1145-1145.	0.6	6
197	Immune Checkpoint Blockade Combinations As Promising Strategy for Cancer Immunotherapy in Multiple Myeloma Patients. <i>Blood</i> , 2016, 128, 2059-2059.	0.6	1
198	A Comparative Study of Biosimilar Filgrastim Versus Originator G-CSF for CD34+ Cells Mobilization and Autografting in Hematological Malignancies. <i>Blood</i> , 2016, 128, 2183-2183.	0.6	1

#	ARTICLE	IF	CITATIONS
199	Extracellular Vesicles as Potential Biomarker for Acute Graft-Versus-Host-Disease. <i>Blood</i> , 2016, 128, 2239-2239.	0.6	1
200	Prognostic Impact of Minimal Residual Disease By ASO-RQ-PCR in Multiple Myeloma: A Pooled Analysis of 2 Phase III Studies in Patients Treated with Lenalidomide after Front-Line Therapy. <i>Blood</i> , 2016, 128, 4409-4409.	0.6	5
201	Upfront Single Versus Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95) Tj ETQq1 0.0.784314.orgBT / 011	0.6	1
202	Flowcytometric Minimal Residual Disease Assessment in the EMN-02/HOVON-95 MM Trial: Used Methods and a Comparison of Their Sensitivity. <i>Blood</i> , 2016, 128, 2072-2072.	0.6	1
203	Prospective Evaluation of 18F-FDG PET/CT As Predictor of Prognosis in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results from the Imaging Sus-Study of the EMN02/HO95 MM Randomized Phase III Trial. <i>Blood</i> , 2016, 128, 992-992.	0.6	0
204	Prolonged Follow-up Confirmed a Role for Upfront Tandem Auto-Allo Transplant in Multiple Myeloma Also in the Era of New Drugs. <i>Blood</i> , 2016, 128, 3469-3469.	0.6	0
205	An Integrated Analysis of Cardio-Vascular Adverse Events of Carfilzomib, Cyclophosphamide and Dexamethasone in Elderly Newly Diagnosed Myeloma Patients Enrolled in 3 Phase I/II Trials. <i>Blood</i> , 2016, 128, 3336-3336.	0.6	0
206	ATP-Binding-Cassette A1 Regulates Extracellular Isopentenyl Pyrophosphate Release and $V\beta 9V\beta 2$ T-Cell Activation By Dendritic Cells. <i>Blood</i> , 2016, 128, 3709-3709.	0.6	0
207	Impact of Treatment Intensification According to Patient Prognosis: A Pooled Analysis of 3 Randomized Phase III Trials. <i>Blood</i> , 2016, 128, 995-995.	0.6	0
208	Hevlyte and Freelite Tests in Newly Diagnosed Multiple Myeloma: Clinical Utility and Correlations with Clinical Features. <i>Blood</i> , 2016, 128, 5625-5625.	0.6	0
209	Prognostic Implication of Somatic Mutations By Next Generation Sequencing: An Analysis from the Mmr1 Compass Study in Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2016, 128, 2079-2079.	0.6	0
210	Post-Remission Treatment with Autologous or Allogeneic Bone Marrow Transplantation or Intensive Chemotherapy in Younger AML Patients: Long-Term Follow-up Results of the EORTC/Gimema AML-8A Study. <i>Blood</i> , 2016, 128, 2288-2288.	0.6	2
211	HIF-1 α Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target. <i>Blood</i> , 2016, 128, 305-305.	0.6	0
212	Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells, Also Overcoming Intrinsic and Stromal Cells-Mediated Fludarabine Resistance. <i>Blood</i> , 2016, 128, 3210-3210.	0.6	0
213	Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study. <i>Stem Cell Research and Therapy</i> , 2015, 6, 64.	2.4	25
214	Differences among young adults, adults and elderly chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2015, 26, 185-192.	0.6	72
215	Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation. <i>Bone Marrow Transplantation</i> , 2015, 50, 673-678.	1.3	21
216	Clinical impact of immunophenotypic remission after allogeneic hematopoietic cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2015, 50, 511-516.	1.3	6

#	ARTICLE	IF	CITATIONS
217	Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs. Expert Opinion on Biological Therapy, 2015, 15, 857-872.	1.4	18
218	Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival. Leukemia, 2015, 29, 689-695.	3.3	75
219	Anergic bone marrow V β 9V α 2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma. OncoImmunology, 2015, 4, e1047580.	2.1	58
220	Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 2015, 33, 3459-3466.	0.8	138
221	Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma. Journal of Molecular Diagnostics, 2015, 17, 652-660.	1.2	115
222	Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncology, The, 2015, 16, 1617-1629.	5.1	289
223	Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCyd) in Elderly Newly Diagnosed Multiple Myeloma Patients: Results of a Phase 2 Study. Blood, 2015, 126, 1828-1828.	0.6	4
224	Autologous Transplantation Versus Cyclophosphamide-Lenalidomide-Prednisone Followed By Lenalidomide-Prednisone Versus Lenalidomide Maintenance in Multiple Myeloma: Long-Term Results of a Phase III Trial. Blood, 2015, 126, 392-392.	0.6	4
225	Infection Complications in 476 Patients with Newly Diagnosed Multiple Myeloma Treated with Lenalidomide or Bortezomib Combinations. Blood, 2015, 126, 5365-5365.	0.6	3
226	Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells. Oncotarget, 2015, 6, 29833-29846.	0.8	33
227	The Hypoxia-Inducible Factor-1alpha Is Constitutively Upregulated in TP53 Disrupted CLL Cells: A Potential Target to Overcome Fludarabine Resistance. Blood, 2015, 126, 2925-2925.	0.6	0
228	Highly Sensitive Droplet Digital PCR for MYD88L265P Mutation Detection and Minimal Residual Disease Monitoring in Waldenström Macroglobulinemia. Blood, 2015, 126, 2645-2645.	0.6	0
229	Analysis of Final Data from the Multinational, Non-Interventional, Observational Emmos Study (NCT01241396) in Patients (Pts) with Multiple Myeloma (MM) in Real-World Clinical Practice. Blood, 2015, 126, 3034-3034.	0.6	1
230	Significant Survival Improvement with Maintenance in Patients Achieving a Complete Response: Pooled Analysis of 4 Italian Phase III Trials in Newly Diagnosed Multiple Myeloma Patients. Blood, 2015, 126, 1974-1974.	0.6	0
231	Impact of Complete Response on Survival with Either Autologous Stem Cell Transplantation or Conventional Chemotherapy: Results of a Pooled Analysis of 5 Phase III Trials in Newly Diagnosed Multiple Myeloma Patients. Blood, 2015, 126, 927-927.	0.6	2
232	Hematopoietic Cell Transplantation Comorbidity Index As Prognostic Variable in Patients with Invasive Fungal Infections. Blood, 2015, 126, 5526-5526.	0.6	0
233	Minimal Residual Disease Detection By Multiparametric Flow Cytometry in Newly Diagnosed Multiple Myeloma Patients: A Preliminary Analysis of the EMN02/HO95 MM Study. Blood, 2015, 126, 1760-1760.	0.6	1
234	European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica, 2014, 99, 232-242.	1.7	185

#	ARTICLE	IF	CITATIONS
235	Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. <i>Leukemia</i> , 2014, 28, 222-225.	3.3	77
236	Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective caseâ€matched study. <i>American Journal of Hematology</i> , 2014, 89, 355-362.	2.0	24
237	MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients. <i>British Journal of Haematology</i> , 2014, 164, 841-850.	1.2	20
238	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. <i>Lancet Oncology</i> , The, 2014, 15, 333-342.	5.1	256
239	Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. <i>Leukemia</i> , 2014, 28, 1299-1307.	3.3	257
240	<i>Trichoderma</i> species fungemia after highâ€dose chemotherapy and autologous stem cell transplantation: a case report. <i>Transplant Infectious Disease</i> , 2014, 16, 653-657.	0.7	9
241	European Perspective on Multiple Myeloma Treatment Strategies in 2014. <i>Oncologist</i> , 2014, 19, 829-844.	1.9	90
242	Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival. <i>Journal of Clinical Oncology</i> , 2014, 32, 634-640.	0.8	198
243	Circulating miRNA markers show promise as new prognosticators for multiple myeloma. <i>Leukemia</i> , 2014, 28, 1922-1926.	3.3	55
244	Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents. <i>Annals of Hematology</i> , 2014, 93, 1391-1400.	0.8	27
245	Autologous Transplantation and Maintenance Therapy in Multiple Myeloma. <i>New England Journal of Medicine</i> , 2014, 371, 895-905.	13.9	683
246	High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib. <i>Haematologica</i> , 2014, 99, e14-e16.	1.7	42
247	Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. <i>Blood</i> , 2014, 124, 63-69.	0.6	126
248	Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. <i>Haematologica</i> , 2014, 99, 1114-1122.	1.7	42
249	Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies. <i>Haematologica</i> , 2014, 99, 1611-1617.	1.7	29
250	Bortezomib (BOR)-Thalidomide-Dexamethasone (VTD) and High-Dose Melphalan (HDM) As First Line Treatment for Multiple Myeloma (MM) Is Associated with a Lower Rate of Second Primary Malignancies (SPMs) Compared to TD Plus HDM. <i>Blood</i> , 2014, 124, 1182-1182.	0.6	2
251	Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCd) in Newly Diagnosed Multiple Myeloma Patients: A Phase I- II Study. <i>Blood</i> , 2014, 124, 175-175.	0.6	4
252	Impact of Autologous Transplantation Vs. Chemotherapy Plus Lenalidomide in Newly Diagnosed Myeloma According to Patient Prognosis: Results of a Pooled Analysis of 2 Phase III Trials. <i>Blood</i> , 2014, 124, 198-198.	0.6	3

#	ARTICLE	IF	CITATIONS
253	Circulating Mir-130a in Multiple Myeloma and Extramedullary Myeloma Patients. <i>Blood</i> , 2014, 124, 2043-2043.	0.6	3
254	Doublet Vs Triplet Lenalidomide-Containing Regimens in Newly Diagnosed Myeloma Patients, Younger or Older Than 75 Years: Subgroup Analysis of a Phase III Study. <i>Blood</i> , 2014, 124, 2110-2110.	0.6	5
255	In Multiple Myeloma, Minimal Residual Disease (MRD) Is an Early Predictor of Progression and Is Modulated By Maintenance Therapy with Lenalidomide. <i>Blood</i> , 2014, 124, 3394-3394.	0.6	2
256	Cell-Free DNA for Minimal Residual Disease Monitoring in Multiple Myeloma Patients. <i>Blood</i> , 2014, 124, 3423-3423.	0.6	5
257	Prospective Molecular Monitoring of Minimal Residual Disease after Non-Myeloablative Allografting in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2014, 124, 44-44.	0.6	1
258	Continuous treatment (CT) versus fixed duration of therapy (FDT) in newly diagnosed myeloma patients: PFS1, PFS2, OS endpoints.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8515-8515.	0.8	6
259	The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespective of the disease status. <i>Haematologica</i> , 2014, 99, 1605-1610.	1.7	27
260	The Combination of Frailty and ISS Scores Identifies a Simple Prognostic Index for Overall Survival in Elderly Patients Treated with Novel Agents-Based Induction Therapy. <i>Blood</i> , 2014, 124, 4740-4740.	0.6	0
261	Multicolor Flowcytometry Analysis of Hematopoietic Stem and Progenitor Cells Subsets Among Basal and Mobilized Peripheral CD34+ Cells. <i>Blood</i> , 2014, 124, 5117-5117.	0.6	0
262	The Mevalonate Metabolic Pathway and the CXCL12/CXCR4 Axis Reciprocally Interact and Are Implicated in Fludarabine Resistance of Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2014, 124, 833-833.	0.6	0
263	Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: A retrospective study on 91 unselected patients. <i>American Journal of Hematology</i> , 2013, 88, 838-842.	2.0	6
264	Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma. <i>Annals of Hematology</i> , 2013, 92, 1503-1511.	0.8	19
265	Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles. <i>American Journal of Hematology</i> , 2013, 88, 16-23.	2.0	60
266	Allogeneic Hematopoietic Cell Transplantation from Unrelated Donors in Multiple Myeloma: Study from the Italian Bone Marrow Donor Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 940-948.	2.0	20
267	Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma. <i>Therapeutic Advances in Hematology</i> , 2013, 4, 189-198.	1.1	15
268	Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome. <i>Clinical Cancer Research</i> , 2013, 19, 3247-3258.	3.2	50
269	Decreasing Frequency of Osteonecrosis of the Jaw in Cancer and Myeloma Patients Treated with Bisphosphonates: The Experience of the Oncology Network of Piedmont and Aosta Valley (North-Western Italy). <i>ISRN Oncology</i> , 2013, 2013, 1-8.	2.1	14
270	Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma. <i>Cancer</i> , 2013, 119, 971-977.	2.0	13

#	ARTICLE	IF	CITATIONS
271	Lenalidomide~prednisone induction followed by lenalidomide~melphalan~prednisone consolidation and lenalidomide~prednisone maintenance in newly diagnosed elderly unfit myeloma patients. <i>Leukemia</i> , 2013, 27, 695-701.	3.3	31
272	Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia. <i>Clinical Cancer Research</i> , 2013, 19, 3130-3142.	3.2	86
273	Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. <i>Blood</i> , 2013, 122, 2799-2806.	0.6	80
274	Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. <i>Blood</i> , 2013, 122, 1376-1383.	0.6	74
275	The impact of response on bone-directed therapy in patients with multiple myeloma. <i>Blood</i> , 2013, 122, 2974-2977.	0.6	18
276	Cost of Illness in Patients with Multiple Myeloma in Italy: The CoMiM Study. <i>Tumori</i> , 2013, 99, e193-e202.	0.6	14
277	Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. <i>Haematologica</i> , 2013, 98, 980-987.	1.7	193
278	Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. <i>Haematologica</i> , 2013, 98, 87-94.	1.7	73
279	Circulating Mir-16 and Mir-25 As New Prognosticators For Multiple Myeloma. <i>Blood</i> , 2013, 122, 1853-1853.	0.6	8
280	Maintenance Therapy With Lenalidomide Significantly Improved Survival Of Yong Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2013, 122, 2089-2089.	0.6	11
281	Persistent Improvement In Clinical Outcomes With Bortezomib-Thalidomide-Dexamethasone Vs Thalidomide-Dexamethasone Incorporated Into Double Autologous Transplantation For Multiple Myeloma: An Updated Analysis Of Phase 3 Gimema-MMY-3006 Study. <i>Blood</i> , 2013, 122, 2090-2090.	0.6	6
282	Immunophenotypic Response After Allografting In Multiple Myeloma. <i>Blood</i> , 2013, 122, 3371-3371.	0.6	1
283	Retrospective Analysis Of 204 Patients With Polycythemia VERA: The International Working Group For Myeloproliferative Neoplasm Research and Treatment (IWG-MRT) Prognostic Score Is A Good Predictor Of Survival and Prognosis. <i>Blood</i> , 2013, 122, 4072-4072.	0.6	1
284	Improved Igh-Based MRD Detection By Using Droplet Digital PCR: a Comparison With Real Time Quantitative PCR In MCL and MM. <i>Blood</i> , 2013, 122, 4290-4290.	0.6	2
285	A Randomized Phase 3 Trial Of Melphalan-Lenalidomide-Prednisone (MPR) Or Cyclophosphamide-Prednisone-Lenalidomide (CPR) Vs Lenalidomide Plus Dexamethasone (Rd) In Elderly Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2013, 122, 536-536.	0.6	13
286	Reduced Dose-Intensity Subcutaneous Bortezomib Plus Prednisone (VP) Or Plus Cyclophosphamide (VCP) Or Plus Melphalan (VMP) For Newly Diagnosed Multiple Myeloma Patients Older Than 75 Years Of Age. <i>Blood</i> , 2013, 122, 539-539.	0.6	17
287	A Phase II Study With Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) For Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2013, 122, 685-685.	0.6	8
288	A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2013, 122, 687-687.	0.6	15

#	ARTICLE	IF	CITATIONS
289	A Phase III Study Of ASCT Vs Cyclophosphamide-Lenalidomide-Dexamethasone and Lenalidomide-Prednisone Maintenance Vs Lenalidomide Alone In Newly Diagnosed Myeloma Patients. <i>Blood</i> , 2013, 122, 763-763.	0.6	20
290	Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8509-8509.	0.8	15
291	Second primary malignancies (SPM) in newly diagnosed myeloma (MM) patients treated with lenalidomide (Len): Meta-analysis of 6,383 individual patient data (IPD).. <i>Journal of Clinical Oncology</i> , 2013, 31, 8517-8517.	0.8	6
292	Granulocyte-Macrophage Progenitors (GMPs) Express Low Adhesive Potential and High CXCR-4 Levels. <i>Blood</i> , 2013, 122, 3698-3698.	0.6	0
293	Long-Term Molecular Results Of The Gimema VEL-03-096 Trial: Molecular Remission Achievement and Loss Are Major Outcome Predictors. <i>Blood</i> , 2013, 122, 2077-2077.	0.6	0
294	Paroxysmal Nocturnal Hemoglobinuria With Budd-Chiari Syndrome Treated With Complement Inhibitor Eculizumab; A Case Report. <i>Blood</i> , 2013, 122, 4800-4800.	0.6	0
295	Minimal Residual Disease Monitoring During Maintenance In Multiple Myeloma Patients. <i>Blood</i> , 2013, 122, 3126-3126.	0.6	2
296	Cost of illness in patients with multiple myeloma in Italy: the CoMiM study. <i>Tumori</i> , 2013, 99, e193-202.	0.6	8
297	European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses. <i>Oncologist</i> , 2012, 17, 592-606.	1.9	48
298	Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 1209-1222.	1.5	9
299	Dysfunctional $V\alpha 39V\beta 2$ T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. <i>Blood</i> , 2012, 120, 3271-3279.	0.6	51
300	Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. <i>Blood</i> , 2012, 119, 933-939.	0.6	260
301	Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2012, 120, 9-19.	0.6	305
302	Multicenter Experience Using Total Lymphoid Irradiation and Antithymocyte Globulin as Conditioning for Allografting in Hematological Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1600-1607.	2.0	25
303	Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2012, 53, 1722-1727.	0.6	43
304	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. <i>Leukemia</i> , 2012, 26, 149-157.	3.3	664
305	How to Manage Neutropenia in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 5-11.	0.2	40
306	Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: Evidence for premature aging of the myeloid compartment. <i>Mechanisms of Ageing and Development</i> , 2012, 133, 479-488.	2.2	9

#	ARTICLE	IF	CITATIONS
307	Current treatment strategies with lenalidomide in multiple myeloma and future perspectives. <i>Future Oncology</i> , 2012, 8, 1223-1238.	1.1	11
308	Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes. <i>Haematologica</i> , 2012, 97, 849-853.	1.7	14
309	SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma. <i>Annals of Hematology</i> , 2012, 91, 875-888.	0.8	28
310	Primary plasma cell leukemia in the era of new drugs: Has something changed?. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 82, 141-149.	2.0	18
311	Long-term follow-up of myelodysplastic syndrome patients with moderate/severe anaemia receiving human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D ₃ : independent positive impact of erythroid response on survival. <i>British Journal of Haematology</i> , 2012, 158, 99-107.	1.2	8
312	Overall Survival Benefit for Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance with Bortezomib-Thalidomide (VMPT-VT) Versus Bortezomib-Melphalan-Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2012, 120, 200-200.	0.6	13
313	Analysis of Transcriptome, Mirnome and Genomic Profiles in Association with Clinical Outcome in a Prospective Series of Primary Plasma Cell Leukemia. <i>Blood</i> , 2012, 120, 3938-3938.	0.6	1
314	Bortezomib-Thalidomide-Dexamethasone Incorporated Into Autotransplantation Is Associated with More Favorable Outcomes After Relapse in Comparison with Thalidomide-Dexamethasone Plus Autotransplantation in Multiple Myeloma. <i>Blood</i> , 2012, 120, 4210-4210.	0.6	1
315	Pomalidomide Cyclophosphamide and Prednisone (PCP) Treatment for Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2012, 120, 446-446.	0.6	6
316	Lenalidomide and Low Dose Dexamethasone As First Line Therapy for Newly Diagnosed Patients with Primary Plasma Cell Leukemia. <i>Blood</i> , 2012, 120, 729-729.	0.6	1
317	Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients. <i>Blood</i> , 2012, 120, 730-730.	0.6	4
318	Next-Generation Sequencing and Real-Time Quantitative PCR for Minimal Residual Disease (MRD) Detection Using the Immunoglobulin Heavy Chain Variable Region: A Methodical Comparison in Acute Lymphoblastic Leukemia (ALL), Mantle Cell Lymphoma (MCL) and Multiple Myeloma (MM). <i>Blood</i> , 2012, 120, 788-788.	0.6	1
319	A Retrospective Real-Life Analysis of Chronic Myeloid Leukemia Patients in Suboptimal Response to Imatinib. <i>Blood</i> , 2012, 120, 4446-4446.	0.6	0
320	miRNA in Serum and Bone Marrow Plasma Cells From Multiple Myeloma Patients.. <i>Blood</i> , 2012, 120, 2921-2921.	0.6	0
321	The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2012, 120, 3881-3881.	0.6	0
322	Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA). <i>Blood</i> , 2012, 120, 3878-3878.	0.6	0
323	High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma. <i>Blood</i> , 2012, 120, 4204-4204.	0.6	0
324	Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. <i>Blood</i> , 2011, 117, 4701-4705.	0.6	377

#	ARTICLE	IF	CITATIONS
325	Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy. <i>Leukemia</i> , 2011, 25, 1627-1631.	3.3	51
326	Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 986-993.	0.8	302
327	Management of Myeloma: An Italian Perspective. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S82-S86.	0.2	0
328	IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. <i>Leukemia</i> , 2011, 25, 828-837.	3.3	61
329	Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. <i>Blood</i> , 2011, 117, 3025-3031.	0.6	247
330	International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. <i>Blood</i> , 2011, 117, 6063-6073.	0.6	282
331	Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. <i>Blood</i> , 2011, 117, 6721-6727.	0.6	113
332	Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). <i>Blood</i> , 2011, 118, 4519-4529.	0.6	309
333	The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens. <i>Cancer</i> , 2011, 117, 1884-1890.	2.0	13
334	Update on the MONITOR-GCSF study of biosimilar filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia in cancer patients: Protocol amendments. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 77, 198-200.	2.0	15
335	Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. <i>Blood</i> , 2011, 118, 5759-5766.	0.6	34
336	Immune Modulation by Zoledronic Acid in Human Myeloma: An Advantageous Cross-Talk between $\hat{V}^{\hat{3}9}\hat{V}^{\hat{2}}$ T Cells, $\hat{I}^{\hat{2}}$ CD8+ T Cells, Regulatory T Cells, and Dendritic Cells. <i>Journal of Immunology</i> , 2011, 187, 1578-1590.	0.4	77
337	Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma. <i>Leukemia</i> , 2011, 25, 872-874.	3.3	56
338	Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple Myeloma: A Study from the Italian Bone Marrow Transplantation Donor Registry. <i>Blood</i> , 2011, 118, 2009-2009.	0.6	1
339	Final Results of a Phase II Study Evaluating Lenalidomide in Combination with Low Dose Dexamethasone As First Line Therapy for Primary Plasma Cell Leukemia. <i>Blood</i> , 2011, 118, 2925-2925.	0.6	6
340	Melphalan/Prednisone/Lenalidomide (MPR) Versus High-Dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Multiple Myeloma (MM) Patients <65 Years: Results of a Randomized Phase III Study. <i>Blood</i> , 2011, 118, 3069-3069.	0.6	11
341	A Phase I/II Study of Pomalidomide-Cyclophosphamide-Prednisone (PCP) in Patients with Multiple Myeloma Relapsed/Refractory to Lenalidomide. <i>Blood</i> , 2011, 118, 632-632.	0.6	4
342	LONG-TERM RESULTS of the GIMEMA VTD Consolidation TRIAL In Autografted MULTIPLE Myeloma PATIENTS (VEL-03-096): IMPACT of Minimal RESIDUAL DISEASE Detection by REAL Time Quantitative PCR On LATE Recurrences and Overall SURVIVAL. <i>Blood</i> , 2011, 118, 827-827.	0.6	6

#	ARTICLE	IF	CITATIONS
343	Second Primary Malignancies in Newly Diagnosed Multiple Myeloma Patients Treated with Lenalidomide: Analysis of Pooled Data in 2459 Patients. <i>Blood</i> , 2011, 118, 996-996.	0.6	3
344	Bortezomib- and Thalidomide-Induced Peripheral Neuropathy (PN) in Multiple Myeloma (MM): Clinical and Molecular Analysis of 474 Patients Treated with Thalidomide-Dexamethasone (TD) or Bortezomib-TD (VTD). <i>Blood</i> , 2011, 118, 1821-1821.	0.6	1
345	Progressive Telomere Shortening Is Part of the Natural History of Chronic Lymphocytic Leukemia (CLL) and Impacts Clinical Outcome. <i>Blood</i> , 2011, 118, 2845-2845.	0.6	0
346	The Mevalonate Pathway As a Metabolic Target to Circumvent Multidrug-Resistance in Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2011, 118, 735-735.	0.6	0
347	A Score Model for Predicting Unsuccessful or Sub-Optimal Peripheral Blood Stem Cell Collections in Multiple Myeloma Based on a Retrospective Analysis of 1,039 Patients Receiving Novel Agents As Induction Therapy and Cyclophosphamide Plus G-CSF As Mobilizing Regimen,. <i>Blood</i> , 2011, 118, 4044-4044.	0.6	0
348	Melphalan 200 mg/m ² versus melphalan 100 mg/m ² in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. <i>Blood</i> , 2010, 115, 1873-1879.	0.6	87
349	Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. <i>Blood</i> , 2010, 116, 4745-4753.	0.6	361
350	A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs. <i>Annals of Hematology</i> , 2010, 89, 691-699.	0.8	57
351	Early CPAP prevents evolution of acute lung injury in patients with hematologic malignancy. <i>Intensive Care Medicine</i> , 2010, 36, 1666-1674.	3.9	152
352	Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, 2803-2815.	1.6	228
353	Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. <i>European Journal of Haematology</i> , 2010, 84, 223-228.	1.1	77
354	Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma. <i>European Journal of Haematology</i> , 2010, 85, 200-208.	1.1	8
355	Telomeres and telomerase in normal and malignant B-cells. <i>Hematological Oncology</i> , 2010, 28, 157-167.	0.8	14
356	AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3 β activation and RNA polymerase II inhibition. <i>Oncogene</i> , 2010, 29, 2325-2336.	2.6	120
357	Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma. <i>Leukemia</i> , 2010, 24, 1037-1042.	3.3	39
358	Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. <i>Leukemia</i> , 2010, 24, 1121-1127.	3.3	677
359	Comparative assessment of telomere length before and after hematopoietic SCT: role of grafted cells in determining post-transplant telomere status. <i>Bone Marrow Transplantation</i> , 2010, 45, 505-512.	1.3	14
360	"ROLE OF ALLOGENEIC TRANSPLANTATION IN MULTIPLE MYELOMA IN THE ERA OF NEW DRUGS". <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2010, 2, e2010013.	0.5	1

#	ARTICLE	IF	CITATIONS
361	Survival and Years of Life Lost in Different Age Cohorts of Patients With Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2010, 28, 1599-1605.	0.8	142
362	Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients. <i>Journal of Clinical Oncology</i> , 2010, 28, 800-807.	0.8	166
363	Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma. <i>Journal of Clinical Oncology</i> , 2010, 28, 2077-2084.	0.8	246
364	Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective. <i>Oncologist</i> , 2010, 15, 6-25.	1.9	85
365	European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. <i>Leukemia and Lymphoma</i> , 2010, 51, 2006-2011.	0.6	14
366	Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. <i>Haematologica</i> , 2010, 95, 1144-1149.	1.7	40
367	Hepatitis B Virus Reactivation and Efficacy of Prophylaxis with Lamivudine in Patients Undergoing Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 809-817.	2.0	41
368	Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match study. <i>Leukemia and Lymphoma</i> , 2010, 51, 1444-14449.	0.6	3
369	Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. <i>Leukemia and Lymphoma</i> , 2010, 51, 1424-1443.	0.6	49
370	Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 5101-5109.	0.8	400
371	A Phase III Study of Enoxaparin Vs Aspirin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Lenalidomide-Based Regimen.. <i>Blood</i> , 2010, 116, 1092-1092.	0.6	17
372	A Multicenter, Open Label Study of Oral Lenalidomide and Prednisone (RP) Followed by Oral Lenalidomide Melphalan and Prednisone (MPR) and Oral Lenalidomide Maintenance In Newly Diagnosed Elderly Multiple Myeloma Patients. <i>Blood</i> , 2010, 116, 1940-1940.	0.6	5
373	Melphalan, Thalidomide and Prednisone (MPT) Combined with Oral Panobinostat In Patients with Relapsed/Refractory MM: a Phase I-II Study. <i>Blood</i> , 2010, 116, 3019-3019.	0.6	5
374	A Phase III Study to Compare Melphalan, Prednisone, Lenalidomide (MPR) Versus Melphalan 200 Mg/m2 and Autologous Transplantation (MEL200) In Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2010, 116, 3573-3573.	0.6	3
375	Long-Term Follow up of a Comparison of Non-Myeloablative Allografting with Autografting for Newly Diagnosed Myeloma. <i>Blood</i> , 2010, 116, 525-525.	0.6	2
376	Bortezomib, Melphalan, Prednisone and Thalidomide Followed by Maintenance with Bortezomib and Thalidomide (VMPT-VT) for Initial Treatment of Elderly Multiple Myeloma Patients: Updated Follow-up and Impact of Prognostic Factors. <i>Blood</i> , 2010, 116, 620-620.	0.6	10
377	Bortezomib-Based Induction Treatments Improve Outcomes of Newly Diagnosed Multiple Myeloma Patients with High-Risk Cytogenetic Abnormalities. <i>Blood</i> , 2010, 116, 781-781.	0.6	6
378	Identification by Serological Proteome Analysis (SERPA) of Tumor-Associated Antigens Eliciting Antibody Responses In Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2010, 116, 917-917.	0.6	0

#	ARTICLE	IF	CITATIONS
379	Immune Reconstitution and Thymic Function After Reduced Intensity Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2010, 116, 1254-1254.	0.6	5
380	Long Term Follow-up of a Population of Low-Intermediate Risk Myelodysplastic Syndrome Patients Treated with a Combination of Recombinant Erythropoietin, 13-Cis-Retinoic Acid and Dihydroxylated Vitamin D3 Confirms the Positive Role of Erythroid Response on Survival. <i>Blood</i> , 2010, 116, 4968-4968.	0.6	4
381	Hematological Testing Is Not Required with Every Dose of Bortezomib In Patients with Adequate Blood Counts at the Start of Each Cycle. <i>Blood</i> , 2010, 116, 1963-1963.	0.6	1
382	Physician-Patient Relationship: Intervention Opportunities for Multiple Myeloma patients' Needs. <i>Blood</i> , 2010, 116, 2564-2564.	0.6	1
383	Achievement of Complete Response Is a Strong Prognostic Factor In Elderly Newly Diagnosed Myeloma: Retrospective Analysis of 1175 Patients. <i>Blood</i> , 2010, 116, 1949-1949.	0.6	1
384	COMPARISON Among Citology, Histology, and FLOW Cytometry IN Evaluating Blast VALUES IN Myelodysplastic Syndromes (MDS). Survey FROM the Italian "PIEMONTE MDS REGISTRY". <i>Blood</i> , 2010, 116, 4028-4028.	0.6	0
385	High Expression of mRNA and Gene Amplification of Met In Myeloma Plasma Cells Characterize a More Aggressive Disease. <i>Blood</i> , 2010, 116, 1898-1898.	0.6	0
386	The Defective Proliferation of Vgamma9Vdelta2 T Cells to Zoledronic Acid In Chronic Lymphocytic Leukemia (CLL) Is a Powerful Time to First Treatment (TFT) Predictor Associated with the IGHV Mutational Status. <i>Blood</i> , 2010, 116, 3602-3602.	0.6	0
387	IGH Repertoire Analysis In Multiple Myeloma (MM): Lack of Intra-Disease Homology and Occasional Clustering with Sequences of Other B-Cell Neoplasms Sharing Identical Geographical Origin. <i>Blood</i> , 2010, 116, 2951-2951.	0.6	0
388	IGHV Unmutated Chronic Lymphocytic Leukemia (CLL) B Cells Are More Susceptible to Spontaneous Apoptosis Than Mutated CLL B Cells and Are Subject to the Anti-Apoptotic Effect of Environmental Signals. <i>Blood</i> , 2010, 116, 2431-2431.	0.6	0
389	Severe Telomeric Erosion In Ph-Negative Hematopoiesis After Successful CML Treatment: Association with Acquired Cytogenetic Lesions and Hematological Toxicity.. <i>Blood</i> , 2010, 116, 3375-3375.	0.6	2
390	Serum Free Light Chain Ratio, Total IgG Ratio, and Immunofixation Results Are Not Prognostic Factors after Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma. <i>Clinical Chemistry</i> , 2009, 55, 1510-1516.	1.5	33
391	The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. <i>Annals of Oncology</i> , 2009, 20, 1303-1317.	0.6	201
392	Preclinical Studies in Support of Defibrotide for the Treatment of Multiple Myeloma and Other Neoplasias. <i>Clinical Cancer Research</i> , 2009, 15, 1210-1221.	3.2	47
393	Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts. <i>European Journal of Haematology</i> , 2009, 82, 93-105.	1.1	21
394	Efficacy of a combination of human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2009, 144, 342-349.	1.2	20
395	Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose modification guideline. <i>British Journal of Haematology</i> , 2009, 144, 895-903.	1.2	289
396	International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. <i>Leukemia</i> , 2009, 23, 215-224.	3.3	686

#	ARTICLE	IF	CITATIONS
397	Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia. <i>Leukemia</i> , 2009, 23, 1062-1072.	3.3	97
398	The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. <i>Leukemia</i> , 2009, 23, 1131-1138.	3.3	111
399	International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. <i>Leukemia</i> , 2009, 23, 1716-1730.	3.3	136
400	International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of pexiafor (AMD 3100). <i>Leukemia</i> , 2009, 23, 1904-1912.	3.3	207
401	Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Myeloma: Kinetics of Neutropenia and Thrombocytopenia and Time-to-Event Results. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 145-150.	1.4	36
402	The Activity of Spanish and Italian Myeloma Groups. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S36-S39.	1.4	0
403	New Combination Approaches for Multiple Myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S42-S43.	1.4	0
404	Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma. <i>Seminars in Hematology</i> , 2009, 46, 158-165.	1.8	14
405	First-Line Treatment of Multiple Myeloma in Elderly Patients: the GIMEMA (Gruppo Italiano Malattie Tj ETQq1 1 0.784314 rgBT /Overlock 10, 906-922.	1.0	9
406	Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. <i>Blood</i> , 2009, 113, 3375-3382.	0.6	92
407	Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Followed by Maintenance with Bortezomib and Thalidomide for Initial Treatment of Elderly Multiple Myeloma Patients.. <i>Blood</i> , 2009, 114, 128-128.	0.6	16
408	Clinical Outcomes According to Genomic Abnormalities in 566 Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib-Based Regimens.. <i>Blood</i> , 2009, 114, 1868-1868.	0.6	2
409	A Prospective Randomized Phase I/II Study of Lenalidomide, Melphalan, Prednisone and Thalidomide (RMPT) for Relapsed/Refractory Multiple Myeloma Patients.. <i>Blood</i> , 2009, 114, 2864-2864.	0.6	4
410	Sequential Therapy with IMiD's in Relapsed-Refractory Multiple Myeloma Patients.. <i>Blood</i> , 2009, 114, 2888-2888.	0.6	5
411	Sequential Approach with Bortezomib as Induction Before Autologous Transplantation, Followed by Lenalidomide as Consolidation-Maintenance in Untreated Multiple Myeloma Patients.. <i>Blood</i> , 2009, 114, 3419-3419.	0.6	1
412	A Prospective, Randomized Study of Melphalan, Prednisone, Lenalidomide (MPR) versus Melphalan (200) Tj ETQq0 0 0 rgBT /Overlock 10 Analysis.. <i>Blood</i> , 2009, 114, 350-350.	0.6	11
413	A Phase IB, Multi-Center, Open-Label Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma.. <i>Blood</i> , 2009, 114, 3852-3852.	0.6	11
414	The Weekly Infusion of Bortezomib Reduces Peripheral Neuropathy.. <i>Blood</i> , 2009, 114, 3887-3887.	0.6	5

#	ARTICLE	IF	CITATIONS
415	A Phase III Study of Enoxaparin vs Aspirin vs Low-Dose Warfarin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Thalidomide Based-Regimens.. Blood, 2009, 114, 492-492.	0.6	14
416	Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients.. Blood, 2009, 114, 743-743.	0.6	6
417	Correlation Between Clinical Outcome and Disease Kinetics by Quantitative PCR in Myeloma Patients Following Post-Transplant Consolidation with Bortezomib, Thalidomide and Dexamethasone.. Blood, 2009, 114, 960-960.	0.6	3
418	Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Melphalan and Prednisone: A Case-Control Study in Newly Diagnosed Elderly Myeloma Patients.. Blood, 2009, 114, 2877-2877.	0.6	0
419	Induction with New Drugs and Planned Autologous Followed by Non-Myeloablative Allogeneic Transplantation in Newly Diagnosed Myeloma.. Blood, 2009, 114, 4330-4330.	0.6	0
420	Differential Effects of Microenvironmental Elements On Tumor Cells Survival in Chronic Lymphocytic Leukemia Patient Subsets with Good or Poor Prognosis.. Blood, 2009, 114, 2333-2333.	0.6	12
421	Complete Response to First-Line Bortezomib-Thalidomide-Dexamethasone Therapy in Multiple Myeloma Patients with t(4;14): Analysis of Gene Expression Profile.. Blood, 2009, 114, 2811-2811.	0.6	0
422	Met Over-Expression Is a Prognostic Factor for Myeloma Patients Treated with Novel Agents.. Blood, 2009, 114, 1821-1821.	0.6	0
423	Ph-Negative Hematopoiesis Emerging After Successful Treatment of Chronic Myeloid Leukemia Displays Severe and Persistent Telomeric Loss Which Is Particularly Prominent in Patients with Acquired Cytogenetic Abnormalities.. Blood, 2009, 114, 2164-2164.	0.6	0
424	Characteristics of the Immunoglobulin Heavy Chain (IgH) Rearrangement in Multiple Myeloma (MM): An Analysis On 308 Cases.. Blood, 2009, 114, 2808-2808.	0.6	0
425	MPT Vs ThaDD in Very Elderly Patients with Multiple Myeloma: a Case-Match Study.. Blood, 2009, 114, 1835-1835.	0.6	0
426	A Pilot Study of Lenalidomide and Dexamethasone as First Line Therapy in Patients with Primary Plasma Cell Leukemia.. Blood, 2009, 114, 4951-4951.	0.6	0
427	Treatment of newly diagnosed multiple myeloma. Current Hematologic Malignancy Reports, 2008, 3, 107-114.	1.2	0
428	A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer, 2008, 113, 1588-1595.	2.0	163
429	Thalidomide and lenalidomide: Mechanism-based potential drug combinations. Leukemia and Lymphoma, 2008, 49, 1238-1245.	0.6	103
430	Update on Recent Developments for Patients with Newly Diagnosed Multiple Myeloma. Annals of the New York Academy of Sciences, 2008, 1138, 19-21.	1.8	10
431	Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia, 2008, 22, 414-423.	3.3	787
432	Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia, 2008, 22, 842-849.	3.3	163

#	ARTICLE	IF	CITATIONS
433	Defective interleukin-2 induction of lymphokine-activated killer (LAK) activity in peripheral blood T lymphocytes of patients with monoclonal gammopathies. <i>Clinical and Experimental Immunology</i> , 2008, 79, 100-104.	1.1	23
434	Thalidomide for treatment of multiple myeloma: 10 years later. <i>Blood</i> , 2008, 111, 3968-3977.	0.6	294
435	Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. <i>Leukemia and Lymphoma</i> , 2008, 49, 2156-2162.	0.6	143
436	Role of thalidomide in previously untreated patients with multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1569-1580.	1.1	4
437	Defibrotide: a review on clinical use and future development. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 1201-1212.	1.4	6
438	Rituximab Improves the Efficacy of High-Dose Chemotherapy With Autograft for High-Risk Follicular and Diffuse Large B-Cell Lymphoma: A Multicenter Gruppo Italiano Terapie Innovative nei Linfomi Survey. <i>Journal of Clinical Oncology</i> , 2008, 26, 3166-3175.	0.8	68
439	MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 12885-12890.	3.3	507
440	Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10%549 patients from the International Myeloma Working Group. <i>Blood</i> , 2008, 111, 4039-4047.	0.6	190
441	Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. <i>Annals of Oncology</i> , 2008, 19, 1160-1165.	0.6	101
442	Lenalidomide and its role in the management of multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 865-874.	1.1	15
443	Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. <i>Blood</i> , 2008, 112, 3107-3114.	0.6	339
444	Prospective, multicenter randomized GITMO/III trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. <i>Blood</i> , 2008, 111, 4004-4013.	0.6	243
445	Superior Complete Response Rate and Progression-Free Survival after Autologous Transplantation with up-Front Velcade-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2008, 112, 158-158.	0.6	25
446	Bortezomib-Doxorubicin-Dexamethasone as Induction Prior to Reduced Intensity Autologous Transplantation Followed by Lenalidomide as Consolidation/Maintenance in Elderly Untreated Myeloma Patients. <i>Blood</i> , 2008, 112, 159-159.	0.6	17
447	The Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) Predicts Survival and Non-Relapse Mortality in Lymphoma and Myeloma Patients Undergoing Reduced-Intensity or Non-Myeloablative Allogeneic Stem Cell Transplantations .. <i>Blood</i> , 2008, 112, 2144-2144.	0.6	2
448	AT7519, a Novel Small Molecule Multi-Cyclin Dependent Kinase Inhibitor, Induces Apoptosis in Multiple Myeloma VIA GSK3 β . <i>Blood</i> , 2008, 112, 251-251.	0.6	4
449	Oral Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Multiple Myeloma Patients: Kinetics of Neutropenia/Thrombocytopenia and Time to Event Results. <i>Blood</i> , 2008, 112, 2768-2768.	0.6	2
450	Bortezomib and Dexamethasone as Maintenance therapy in Relapse/Refractory multiple myeloma Patients. <i>Blood</i> , 2008, 112, 2771-2771.	0.6	2

#	ARTICLE	IF	CITATIONS
451	A Phase III Study of Enoxaparin Versus Low-Dose Warfarin Versus Aspirin as Thromboprophylaxis for Patients with Newly Diagnosed Multiple Myeloma Treated up-Front with Thalidomide-Containing Regimens. <i>Blood</i> , 2008, 112, 3017-3017.	0.6	17
452	Melphalan 200 Mg/m ² (Mel200) Versus Melphalan 100 Mg/m ² (Mel100) in Newly Diagnosed Myeloma Patients: A Prospective, Randomized Phase III Study. <i>Blood</i> , 2008, 112, 3316-3316.	0.6	1
453	Bortezomib (VEL) Based Regimens in Multiple Myeloma (MM) Patients with Renal Impairment (RI): A Preliminary Retrospective Italian Multicenter Study. <i>Blood</i> , 2008, 112, 3681-3681.	0.6	1
454	Major Shrinking of Residual Tumor Cell Burden and Achievement of Molecular Remissions in Myeloma Patients Undergoing Post-Transplant Consolidation with Bortezomib, Thalidomide and Dexamethasone: A Qualitative and Quantitative PCR Study. <i>Blood</i> , 2008, 112, 3683-3683.	0.6	11
455	A Prospective, Randomized, Phase III Study of Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Versus Bortezomib, Melphalan and Prednisone (VMP) in Elderly Newly Diagnosed Myeloma Patients. <i>Blood</i> , 2008, 112, 652-652.	0.6	33
456	Combination of Lenalidomide, Melphalan, Prednisone and Thalidomide (RMPT) in Relapsed/Refractory Multiple Myeloma: Results of a Multicenter Phase II Clinical Trial. <i>Blood</i> , 2008, 112, 868-868.	0.6	4
457	Telomere Length Is An Independent Predictor of Survival, Treatment Requirement and Richter's Syndrome Transformation in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2008, 112, 1052-1052.	0.6	0
458	Retrospective Analysis on 290 Patients with Polycythemia Vera Referred to a Single Transfusion Centre: Diagnosis Revision According to WHO Criteria and Evaluation of Survival and Complications According to Prognostic Factors and Treatment. <i>Blood</i> , 2008, 112, 5229-5229.	0.6	0
459	Economic and Social Burden of Multiple Myeloma in Italy: The Co.Mi.M. Study. <i>Blood</i> , 2008, 112, 2393-2393.	0.6	0
460	Thymic Function Following Nonmyeloablative Allografting for the Treatment of Hematological Malignancies. <i>Blood</i> , 2008, 112, 4344-4344.	0.6	0
461	Persistent Telomeric Loss and Functional Impairment of Ph-Negative Hematopoiesis after Successful Treatment of Chronic Myelogenous Leukemia. <i>Blood</i> , 2008, 112, 3183-3183.	0.6	0
462	Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA's Italian Multiple Myeloma Network. <i>Journal of Clinical Oncology</i> , 2007, 25, 4459-4465.	0.8	301
463	Melphalan and its role in the management of patients with multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 945-957.	1.1	43
464	Polyclonal Immunoglobulin E Levels Are Correlated with Hemoglobin Values and Overall Survival in Patients with Multiple Myeloma. <i>Clinical Cancer Research</i> , 2007, 13, 5348-5354.	3.2	26
465	A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma. <i>New England Journal of Medicine</i> , 2007, 356, 1110-1120.	13.9	479
466	Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. <i>Blood</i> , 2007, 110, 3557-3560.	0.6	485
467	Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. <i>Blood</i> , 2007, 110, 921-927.	0.6	98
468	MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. <i>Blood</i> , 2007, 110, 3744-3752.	0.6	144

#	ARTICLE	IF	CITATIONS
469	Bortezomib after Allografting in Multiple Myeloma: Association between Neurotoxicity and Cyclosporine Treatment. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 497-499.	2.0	5
470	A new standard of care for elderly patients with myeloma. <i>Lancet, The</i> , 2007, 370, 1191-1192.	6.3	12
471	The treatment of the elderly multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2007, 48, 469-480.	0.6	4
472	Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. <i>Blood</i> , 2007, 109, 2767-2772.	0.6	174
473	Time to first disease progression, but not β_2 -microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy. <i>Cancer</i> , 2007, 110, 824-829.	2.0	19
474	Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients. <i>Leukemia</i> , 2007, 21, 697-705.	3.3	41
475	Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). <i>Leukemia</i> , 2007, 21, 1802-1811.	3.3	66
476	Long-term lymphoma survivors following high-dose chemotherapy and autograft: Evidence of permanent telomere shortening in myeloid cells, associated with marked reduction of bone marrow hematopoietic stem cell reservoir. <i>Experimental Hematology</i> , 2007, 35, 673-681.	0.2	25
477	Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma. <i>European Journal of Haematology</i> , 2007, 78, 330-337.	1.1	25
478	Thalidomide+dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide+dexamethasone: a case-matched study in advanced multiple myeloma. <i>European Journal of Haematology</i> , 2007, 78, 297-302.	1.1	30
479	Phase I Study of AVE1642 Anti IGF-1R Monoclonal Antibody in Patients with Advanced Multiple Myeloma.. <i>Blood</i> , 2007, 110, 1166-1166.	0.6	19
480	The Degree of Telomere Loss in Hematopoietic Cells Correlates with the Risk of Secondary Myelodysplasia/Acute Leukemia Development Following Autologous Stem Cell Transplantation.. <i>Blood</i> , 2007, 110, 1672-1672.	0.6	2
481	Long-Term Follow-Up of the Randomized GITMO/ILL Trial Comparing CHOP-Rituximab vs. High-Dose Therapy with Rituximab (R-HDS) in High Risk Follicular Lymphoma (FL): Updated Results Suggest the Use of R-HDS as Salvage Treatment.. <i>Blood</i> , 2007, 110, 20-20.	0.6	1
482	Defibrotide Counteracts the Modifications of Anti-Thrombotic Phenotype of Endothelial Cells Induced by Thalidomide.. <i>Blood</i> , 2007, 110, 2502-2502.	0.6	2
483	Co-Culture of Myeloma and Endothelial Cells: Defibrotide Downregulates Heparanase and Pro-Angiogenic Growth Factors.. <i>Blood</i> , 2007, 110, 2513-2513.	0.6	1
484	Prospective Evaluation of the Bone Anabolic Effect of Bortezomib in Relapsed Multiple Myeloma (MM) Patients.. <i>Blood</i> , 2007, 110, 2719-2719.	0.6	3
485	A Prospective, Randomized, Phase III Study of Enoxaparin Versus Aspirin Versus Low-Fixed-Dose of Warfarin in Newly Diagnosed Myeloma Patients Treated with Thalidomide-Containing Regimens.. <i>Blood</i> , 2007, 110, 310-310.	0.6	8
486	Antibiotic Prophylaxis Before Dental Procedures Can Reduce ONJ Incidence.. <i>Blood</i> , 2007, 110, 3613-3613.	0.6	2

#	ARTICLE	IF	CITATIONS
487	Bortezomib, Pegylated-Lyposomal-Doxorubicin and Dexamethasone Followed by Melphalan 100 mg/m ² in Elderly Newly Diagnosed Patients: An Interim Analysis.. Blood, 2007, 110, 448-448.	0.6	6
488	Consolidation with Bortezomib, Thalidomide and Dexamethasone Induces Molecular Remissions in Autografted Multiple Myeloma Patients.. Blood, 2007, 110, 530-530.	0.6	11
489	Bortezomib (Velcade®)-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) in Preparation for Autologous Stem-Cell (SC) Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM).. Blood, 2007, 110, 73-73.	0.6	45
490	A Prospective Phase II Study on Tandem Autografting-Nonmyeloablative Allografting for Newly Diagnosed Myeloma: Final Results of the Gruppo Italiano Trapianto Midollo Osseo.. Blood, 2007, 110, 3026-3026.	0.6	0
491	Risk of Hepatitis B and Efficacy of Treatment with Lamivudine in Patients Undergoing Allogeneic Stem Cell Transplant.. Blood, 2007, 110, 1970-1970.	0.6	27
492	Telomere Length of Hematopoietic Cells Following Autologous and Allogeneic Stem Cell Transplant (SCT) Reflects That of Grafted Cells: Can the Transplant of Younger Stem Cells Be Exploited To Rejuvenate Hematopoiesis?.. Blood, 2007, 110, 3025-3025.	0.6	0
493	Disease and Comorbidity Status Predict Outcome after Nonmyeloablative Allografting for Advanced Haematological Malignancies.. Blood, 2007, 110, 4930-4930.	0.6	0
494	Patients with aalPI 2-3 Diffuse Large B-Cell Lymphoma Achieve 75% Long-Term Survival Following First-Line Rituximab-Supplemented High-Dose Sequential Chemotherapy and Autograft: Final Results of the Prospective Phase II GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) Trial.. Blood, 2007, 110, 1889-1889.	0.6	1
495	Non-Hodgkinâ€™s Lymphoma Refractory to First Line Therapy: Incidence, Associated Clinical and Histological Factors, and Outcome among 503 Newly Diagnosed Patients.. Blood, 2007, 110, 1373-1373.	0.6	1
496	Targeting CCR1 for the Treatment of Osteolytic Bone Disease in Multiple Myeloma.. Blood, 2007, 110, 2503-2503.	0.6	0
497	A Phase I/II Trial on Melphalan, Prednisone, Thalidomide and Defribotide Combination in Relapsed/Refractory Multiple Myeloma Patients.. Blood, 2007, 110, 2715-2715.	0.6	0
498	The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia Following Intensive Therapy and Autograft Correlates with the Type of Cells Grafted: A Survey on 1,347 Lymphoma Patients Receiving the High-Dose Sequential (HDS) Program.. Blood, 2007, 110, 1083-1083.	0.6	0
499	An Update of a Comparison of Nonmyeloablative Allografting with Autografting for Newly Diagnosed Myeloma.. Blood, 2007, 110, 482-482.	0.6	1
500	Multiple Myeloma Cell-Osteoblast Interaction Results in Impaired Bone Formation.. Blood, 2007, 110, 4764-4764.	0.6	0
501	Phenotypic and Functional Features of VÎ³9/VÎ²2 T Cells in Chronic Lymphocytic Leukemia Are Strongly Correlated with the Mutational Status of the Immunoglobulin Heavy Chain Variable Region (IgVH) and Metabolic Activity of the Mevalonate Pathway in Tumor Cells.. Blood, 2007, 110, 1131-1131.	0.6	0
502	Review of thalidomide in the treatment of newly diagnosed multiple myeloma. Therapeutics and Clinical Risk Management, 2007, 3, 543-52.	0.9	9
503	Investigational treatments for multiple myeloma. Expert Opinion on Investigational Drugs, 2006, 15, 1565-1582.	1.9	7
504	Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet, The, 2006, 367, 825-831.	6.3	775

#	ARTICLE	IF	CITATIONS
505	Intermediate-Dose Melphalan (100 mg/m ²)/Bortezomib/Thalidomide/Dexamethasone and Stem Cell Support in Patients with Refractory or Relapsed Myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2006, 6, 475-477.	1.4	22
506	Management of Multiple Myeloma with Bortezomib: Experts Review the Data and Debate the Issues. <i>Oncology</i> , 2006, 70, 474-482.	0.9	43
507	Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 374-387.	4.3	103
508	Rituximab Induces Effective Clearance of Minimal Residual Disease in Molecular Relapses of Mantle Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 1270-1276.	2.0	55
509	Dramatic Increase of Tacrolimus Plasma Concentration During Topical Treatment for Oral Graft-Versus-Host Disease. <i>Transplantation</i> , 2006, 82, 1113-1115.	0.5	28
510	Identification of a new allele, HLA-DRB5*0113, through three different molecular biology techniques+. <i>Tissue Antigens</i> , 2006, 67, 427-429.	1.0	3
511	Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 1842-1845.	1.9	43
512	Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial. <i>Leukemia</i> , 2006, 20, 1840-1847.	3.3	18
513	Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide. <i>Leukemia Research</i> , 2006, 30, 283-285.	0.4	17
514	High-Risk Fludarabine-Pretreated B-Cell Chronic Lymphocytic Leukemia's High Response Rate Following Sequential DHAP and Alemtuzumab Administration Though in Absence of Molecular Remission. <i>Medical Oncology</i> , 2006, 23, 359-368.	1.2	6
515	Kaposi's sarcoma triggered by endogenous HHV-8 reactivation after non-myceloablative allogeneic haematopoietic transplantation. <i>European Journal of Haematology</i> , 2006, 76, 342-347.	1.1	29
516	Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma. <i>European Journal of Haematology</i> , 2006, 76, 273-277.	1.1	51
517	Cells carrying nonlymphoma-associated bcl-2/IgH rearrangements (NLBR) are phenotypically related to follicular lymphoma and can establish as long-term persisting clonal populations. <i>Experimental Hematology</i> , 2006, 34, 1680-1686.	0.2	12
518	A Practical Update on the Use of Bortezomib in the Management of Multiple Myeloma. <i>Oncologist</i> , 2006, 11, 51-61.	1.9	102
519	Benefit of Rituximab Addition to High-Dose Programs with Autograft for B-Cell Lymphoma: A Multicenter GITIL Survey on 957 Patients.. <i>Blood</i> , 2006, 108, 207-207.	0.6	3
520	Frontline High Dose Sequential Chemotherapy with Rituximab (R-HDS) and Autologous Stem Cell Transplantation Induces High Rates of Complete Response and Prolongs Survival in Mantle Cell Lymphoma (MCL).. <i>Blood</i> , 2006, 108, 3045-3045.	0.6	13
521	Clinical and Molecular Results of the Multicenter Randomized GITMO-III Trial in Poor Risk Follicular Lymphoma (FL) at Diagnosis: Rituximab-Supplemented High-Dose Sequential Chemotherapy (R-HDS) Is Superior to CHOP-R in Molecular Remissions Rate, EFS and PFS.. <i>Blood</i> , 2006, 108, 325-325.	0.6	2
522	Incidence of Secondary Myelodysplastic Syndrome/Acute Leukemia in 1,266 Lymphoma Patients Following High-Dose Therapy and Autograft: A Study from GITIL (Gruppo Italiano Terapie Innovative nei)		

#	ARTICLE	IF	CITATIONS
523	Defibrotide (DF), an Orally Bioavailable Modulator of Myeloma Tumor-Microenvironment Interactions: Molecular Sequelae and Clinical Implications.. Blood, 2006, 108, 3523-3523.	0.6	5
524	A Multi-Center Phase I/II Study of Melphalan, Prednisone, Thalidomide and Defibrotide in Avanced Multiple Myeloma Patients.. Blood, 2006, 108, 3560-3560.	0.6	2
525	Combination of Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) for Relapsed Multiple Myeloma: Results of a Phase I/II Clinical Trial.. Blood, 2006, 108, 407-407.	0.6	2
526	A Prospective, Randomized, Phase III Study of Melphalan 200 mg/m2 (MEL200) Versus Melphalan 100 mg/m2 (MEL100) in Newly Diagnosed Myeloma Patients.. Blood, 2006, 108, 55-55.	0.6	4
527	Oral Revlimid® Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma: Results of a Multicenter Phase I/II Study.. Blood, 2006, 108, 800-800.	0.6	23
528	Dendritic Cells Can Be Primed to Concurrently Activate Both Unconventional Gamma/delta and Conventional alpha/beta T Cells.. Blood, 2006, 108, 3893-3893.	0.6	0
529	MLN3897, a Novel CCR1 Antagonist, Inhibits Osteoclastogenesis by Blocking Early ERK Activation.. Blood, 2006, 108, 1636-1636.	0.6	0
530	Impact of Early Consolidation with Bortezomib, Thalidomide and Dexamethasone on Molecularly-Detectable Disease in MM Patients in CR or VGPR Following Autologous Transplantation: Uncommon Achievement of Molecular Remission Despite Evidence of Tumor Load Reduction by Real Time PCR.. Blood, 2006, 108, 3100-3100.	0.6	0
531	Unrelated Donor Hematopoietic Cell Transplantation after Non-Myeloablative Conditioning for Patients with High Risk Multiple Myeloma.. Blood, 2006, 108, 3158-3158.	0.6	1
532	Protein Expression and Methylation Status of the CKI p21, p15 and p16 in Adult Acute Lymphoblastic Leukemia (ALL) Patients: Prognostic Implications.. Blood, 2006, 108, 1843-1843.	0.6	0
533	Bortezomib and Plasma Cell Leukemia.. Blood, 2006, 108, 3546-3546.	0.6	1
534	Prognostic Role of Transfusion Requirement and Validation of the IPSS Prognostic System in Myelodysplastic Syndromes.. Blood, 2006, 108, 2622-2622.	0.6	0
535	Immunoglobulin (Ig) Repertoire in Multiple Myeloma: High Frequency of Recurrent Aminoacid Substitutions in the FR2 and CDR2.. Blood, 2006, 108, 3413-3413.	0.6	0
536	A New Acute Monoblastic Leukemia Cell Line Expressing Vascular Endotelial Growth Factor (VEGF) -A and -D and VEGF Receptor-3 (Flt-4).. Blood, 2006, 108, 4496-4496.	0.6	0
537	Regulatory T Cells (Tregs) Are Highly Preserved in Multiple Myeloma Patients and Can Dominate Effector Functions.. Blood, 2006, 108, 658-658.	0.6	0
538	CCR1 Inhibition Impairs Osteoclast Activity and Interaction with Myeloma Cells.. Blood, 2006, 108, 3494-3494.	0.6	5
539	Prolonged Survival of Lymphoma Patients Achieving Complete Remission Following High-Dose Sequential Chemotherapy and Autograft (HDS Program): A GITIL (Gruppo Italiano Terapie Innovative Nei Tj ETQq1 0.0.784314 rgBT / Ov	0.6	1
540	Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. Haematologica, 2006, 91, 837-9.	1.7	38

#	ARTICLE	IF	CITATIONS
541	Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome. <i>Blood</i> , 2005, 105, 4784-4791.	0.6	80
542	Effector $\hat{3}\hat{1}$ T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. <i>Leukemia</i> , 2005, 19, 664-670.	3.3	119
543	Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside. <i>Leukemia</i> , 2005, 19, 1729-1738.	3.3	55
544	Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant. <i>European Journal of Haematology</i> , 2005, 75, 391-395.	1.1	36
545	Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favors the induction of Tr1-like regulatory T $\hat{3}$ cells. <i>European Journal of Immunology</i> , 2005, 35, 1155-1163.	1.6	45
546	Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. <i>Cancer</i> , 2005, 104, 1428-1433.	2.0	77
547	Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. <i>Cancer Cell International</i> , 2005, 5, 18.	1.8	196
548	Real-Time Polymerase Chain Reaction of Immunoglobulin Rearrangements for Quantitative Evaluation of Minimal Residual Disease in Myeloma. , 2005, 113, 145-164.		7
549	The Future Role of Thalidomide in Multiple Myeloma. <i>Acta Haematologica</i> , 2005, 114, 18-22.	0.7	4
550	International Staging System for Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2005, 23, 3412-3420.	0.8	2,404
551	Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma. <i>New England Journal of Medicine</i> , 2005, 352, 2487-2498.	13.9	2,356
552	High CR Rate and Prolonged EFS in aalPI 2 \hat{a} €“ 3 Diffuse Large B-Cell Lymphoma Following High-Dose Sequential Chemotherapy and In Vivo Rituximab-Purged Stem Cell Autografting (R-HDS Regimen): Results of a Prospective Phase II Multicenter Study Sponsored by GITIL (Gruppo Italiano Terapie Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2	0.6	10
553	Prognostic Evaluation of Myelodysplastic Syndromes (MDS): Analysis of Deaths Due to Age-Related Causes.. <i>Blood</i> , 2005, 106, 2543-2543.	0.6	36
554	Complete Reversion of Imatinib-Induced Hepatotoxicity in Chronic Myeloid Leukemia Patients by Low-Intermediate Dose Corticosteroid.. <i>Blood</i> , 2005, 106, 4856-4856.	0.6	3
555	Rituximab-Supplemented High-Dose Sequential Chemotherapy (HDS) Has Superior Response Rate and Event-Free Survival (EFS) Compared to R-CHOP in Poor Risk Follicular Lymphoma (FL) at Diagnosis: Results from a Multicenter Randomized GITMO Trial.. <i>Blood</i> , 2005, 106, 675-675.	0.6	3
556	Oral RevlimidR Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma.. <i>Blood</i> , 2005, 106, 785-785.	0.6	8
557	A Maintenance Therapy with Differentiating Agents and Low-Dose Chemotherapy Increases Remission Duration and Survival in High Risk AML and MDS Patients.. <i>Blood</i> , 2005, 106, 4614-4614.	0.6	0
558	Exhaled Nitric Oxide (eNO) and Pulmonary Function after Total Body Irradiation (TBI) Based Non Myeloablative Conditioning Regimens and Allogeneic Hematopoietic Cell Transplant.. <i>Blood</i> , 2005, 106, 5311-5311.	0.6	0

#	ARTICLE	IF	CITATIONS
559	Oral Melphalan, Prednisone and Thalidomide for Multiple Myeloma.. Blood, 2005, 106, 779-779.	0.6	23
560	Telomere Length Identifies Two Distinct Populations with Different Outcome among VH-Unmutated CLL Patients.. Blood, 2005, 106, 2104-2104.	0.6	0
561	Array-Based Comparative Genomic Hybridization (Array-CGH) in Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL): Recurrent Imbalances within a Highly Heterogeneous Background of Genomic Disruption.. Blood, 2005, 106, 5088-5088.	0.6	0
562	Velcade, Plus Melphalan, Prednisone, and Thalidomide (V-MPT) for Advanced Multiple Myeloma.. Blood, 2005, 106, 2553-2553.	0.6	3
563	Graft-Versus-Lymphoma Effect in Relapsed Peripheral T-Cell Non-Hodgkin's Lymphomas After Reduced-Intensity Conditioning Followed by Allogeneic Transplantation of Hematopoietic Cells. Journal of Clinical Oncology, 2004, 22, 2172-2176.	0.8	301
564	Long-Term Follow-Up of Indolent Lymphoma Patients Treated With High-Dose Sequential Chemotherapy and Autografting: Evidence That Durable Molecular and Clinical Remission Frequently Can Be Attained Only in Follicular Subtypes. Journal of Clinical Oncology, 2004, 22, 1460-1468.	0.8	116
565	VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. Annals of Oncology, 2004, 15, 123-128.	0.6	71
566	Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. The Hematology Journal, 2004, 5, 285-285.	2.0	4
567	Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. The Hematology Journal, 2004, 5, 318-324.	2.0	126
568	Successful management of immune thrombocytopenic purpura with thalidomide in a patient with multiple myeloma. The Hematology Journal, 2004, 5, 456-457.	2.0	11
569	Identification of a new HLA-DRB1 allele in three members of an Italian family. Tissue Antigens, 2004, 64, 210-212.	1.0	4
570	Thalidomide in front line treatment in multiple myeloma: serious risk of venous thromboembolism and evidence for thromboprophylaxis. Journal of Thrombosis and Haemostasis, 2004, 2, 2063-2065.	1.9	25
571	Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. Leukemia, 2004, 18, 139-145.	3.3	63
572	Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m ²). Leukemia, 2004, 18, 133-138.	3.3	30
573	Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features. Acta Neurologica Scandinavica, 2004, 109, 188-193.	1.0	57
574	A Large-Scale Study of Bone Marrow Involvement in Patients with Hodgkin's Lymphoma. Clinical Lymphoma and Myeloma, 2004, 5, 50-55.	2.1	34
575	New drugs for treatment of multiple myeloma. Lancet Oncology, The, 2004, 5, 430-442.	5.1	59
576	Multiple Myeloma and Related Disorders. Lancet Oncology, The, 2004, 5, 765.	5.1	1

#	ARTICLE	IF	CITATIONS
577	Telomere length correlates with histopathogenesis according to the germinal center in mature B-cell lymphoproliferative disorders. <i>Blood</i> , 2004, 103, 4644-4649.	0.6	43
578	Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. <i>Blood</i> , 2004, 104, 3052-3057.	0.6	305
579	A Prospective Randomized Trial of Oral Melphalan, Prednisone, Thalidomide (MPT) vs Oral Melphalan, Prednisone (MP): An Interim Analysis.. <i>Blood</i> , 2004, 104, 207-207.	0.6	24
580	Telomerase Inhibitor BIBR1532 Induces Telomere Shortening and Growth Inhibition in Extra-Germinal Center (GC)-Derived Lymphoid Cell Lines.. <i>Blood</i> , 2004, 104, 3389-3389.	0.6	2
581	Rituximab-Supplemented High-Dose Sequential (HDS) Chemotherapy with Autograft Is Highly Effective in High-Risk (aIPI 2-3) Diffuse Large B-Cell Lymphoma: Results of a Prospective Multicenter Study on 91 Consecutive Patients Treated at Diagnosis.. <i>Blood</i> , 2004, 104, 891-891.	0.6	3
582	Incidence of Invasive Aspergillosis in Allogeneic Stem Cell Transplantation Patients: An Italian Prospective Multicenter Study.. <i>Blood</i> , 2004, 104, 5057-5057.	0.6	0
583	Cyclooxygenase-2 (COX-2) Is Frequently Expressed in Multiple Myeloma (MM) and Is Associated with Poor Outcome.. <i>Blood</i> , 2004, 104, 2450-2450.	0.6	0
584	Long-Term Outcome of High-Dose Sequential Chemotherapy with Autografting (i-HDS) in Follicular Lymphoma at Diagnosis: An Update of the Prospective Multicenter Consecutive Trial of the "Gruppo Italiano Trapianto Di Midollo Osseo" (Gitmo).. <i>Blood</i> , 2004, 104, 903-903.	0.6	0
585	Telomere Length of Hematopoietic Cells in Long-Term Post-Autograft Survivors: No Evidence of Accelerated Replicative Cell Senescence Despite the Persistent Reduction of Both Committed and Immature Progenitor Cell Compartments.. <i>Blood</i> , 2004, 104, 4123-4123.	0.6	0
586	Efficacy of Recombinant Erythropoietin + 13-cis Retinoic Acid + Dihydroxylated Vitamin D3 in the Treatment of Anemia of Low-Intermediate Risk Myelodysplastic Syndrome Patients.. <i>Blood</i> , 2004, 104, 4732-4732.	0.6	0
587	Long-Term Monitoring of Cancer-Free Subjects Carrying Non-Lymphoma Associated bcl2/IgH Rearrangements (NLABR): Prolonged Persistence of Clonal Populations Potentially Related to Follicular Lymphoma (FL).. <i>Blood</i> , 2004, 104, 1373-1373.	0.6	0
588	Bone Marrow-Derived Cell Mobilization with G-CSF and GM-CSF in Patients with Acute Myocardial Infarction: A Pilot Study on Feasibility, Safety and Efficacy.. <i>Blood</i> , 2004, 104, 4170-4170.	0.6	0
589	Telomere Length Has Prognostic Impact in B-Cell Chronic Lymphocytic Leukemia (B-CLL).. <i>Blood</i> , 2004, 104, 4768-4768.	0.6	0
590	Thalidomide and Dexamethasone Is an Effective Salvage Regimen for Myeloma Patients Relapsing after Autologous Transplant.. <i>Blood</i> , 2004, 104, 2396-2396.	0.6	0
591	Low Dose TBI Based Nonmyeloablative Conditionings for Allografting in Multiple Myeloma: Impact of Disease Status at Transplant.. <i>Blood</i> , 2004, 104, 2310-2310.	0.6	0
592	Incidence and Risk-Factors of Secondary Myelodysplastic Syndrome/Acute Leukemia Following High-Dose Chemotherapy and Autograft: A Long-Term Analysis on 307 Lymphoma Patients.. <i>Blood</i> , 2004, 104, 2248-2248.	0.6	0
593	Differentiating agents + low-dose chemotherapy in the management of old/poor prognosis patients with acute myeloid leukemia or myelodysplastic syndrome. <i>Haematologica</i> , 2004, 89, 619-20.	1.7	21
594	Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). <i>Haematologica</i> , 2004, 89, 717-41.	1.7	48

#	ARTICLE	IF	CITATIONS
595	Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone. <i>Experimental Hematology</i> , 2003, 31, 784-788.	0.2	13
596	High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma. <i>Cancer</i> , 2003, 97, 2748-2759.	2.0	71
597	Patients with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting. <i>Cancer</i> , 2003, 98, 983-992.	2.0	18
598	High rate of remission and low rate of disease recurrence in patients with multiple myeloma allografted with PBSC from their HLA-identical sibling donors. <i>Bone Marrow Transplantation</i> , 2003, 31, 767-773.	1.3	15
599	Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2003, 32, 791-793.	1.3	10
600	PCR-Detectable Nonneoplastic Bcl-2/IgH Rearrangements Are Common in Normal Subjects and Cancer Patients at Diagnosis but Rare in Subjects Treated With Chemotherapy. <i>Journal of Clinical Oncology</i> , 2003, 21, 1398-1403.	0.8	35
601	Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. <i>The Hematology Journal</i> , 2003, 4, 379-398.	2.0	374
602	Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. <i>Blood</i> , 2003, 102, 1927-1929.	0.6	176
603	Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. <i>The Hematology Journal</i> , 2003, 4, 379-98.	2.0	86
604	Real-time polymerase chain reaction in multiple myeloma. <i>Experimental Hematology</i> , 2002, 30, 529-536.	0.2	24
605	Qualitative and quantitative polymerase chain reaction detection of the residual myeloma cell contamination after positive selection of CD34+ cells with small- and large-scale Miltenyi cell sorting system. <i>British Journal of Haematology</i> , 2002, 117, 642-645.	1.2	11
606	Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. <i>Haematologica</i> , 2002, 87, 846-50.	1.7	69
607	Severe and long-lasting disruption of T-cell receptor diversity in human myeloma after high-dose chemotherapy and autologous peripheral blood progenitor cell infusion. <i>British Journal of Haematology</i> , 2001, 113, 1051-1059.	1.2	48
608	Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. <i>Leukemia</i> , 2001, 15, 1941-1949.	3.3	49
609	Increased expression of non-functional killer inhibitory receptor CD94 in CD8+ cells of myeloma patients. <i>British Journal of Haematology</i> , 2000, 109, 46-53.	1.2	16
610	Multiple myeloma: the number of reinfused plasma cells does not influence outcome of patients treated with intensified chemotherapy and PBPC support. <i>Bone Marrow Transplantation</i> , 2000, 25, 25-29.	1.3	24
611	Molecular and Clinical Remissions in Multiple Myeloma: Role of Autologous and Allogeneic Transplantation of Hematopoietic Cells. <i>Journal of Clinical Oncology</i> , 1999, 17, 208-208.	0.8	222
612	Dose-Intensive Melphalan With Stem Cell Support (MEL100) Is Superior to Standard Treatment in Elderly Myeloma Patients. <i>Blood</i> , 1999, 94, 1248-1253.	0.6	152

#	ARTICLE	IF	CITATIONS
613	Idiotype Vaccination in Human Myeloma: Generation of Tumor-Specific Immune Responses After High-Dose Chemotherapy. <i>Blood</i> , 1999, 94, 673-683.	0.6	127
614	Idiotype Vaccination in Human Myeloma: Generation of Tumor-Specific Immune Responses After High-Dose Chemotherapy. <i>Blood</i> , 1999, 94, 673-683.	0.6	2
615	Dose-Intensive Melphalan With Stem Cell Support (MEL100) Is Superior to Standard Treatment in Elderly Myeloma Patients. <i>Blood</i> , 1999, 94, 1248-1253.	0.6	1
616	Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 1998, 22, 449-455.	1.3	48
617	DIAGNOSIS, PROGNOSIS, AND STANDARD TREATMENT OF MULTIPLE MYELOMA. <i>Hematology/Oncology Clinics of North America</i> , 1997, 11, 111-131.	0.9	67
618	Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. <i>Nature Genetics</i> , 1997, 17, 226-230.	9.4	322
619	A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. <i>Leukemia</i> , 1997, 11, 1793-1798.	3.3	99
620	Multicyclic, dose-intensive chemotherapy supported by hemopoietic progenitors in refractory myeloma patients. <i>Bone Marrow Transplantation</i> , 1997, 19, 23-29.	1.3	15
621	DISTRIBUTION OF T-CELL SIGNALING MOLECULES IN HUMAN MYELOMA. <i>British Journal of Haematology</i> , 1997, 97, 810-814.	1.2	100
622	Multiple myeloma: reduced plasma cell contamination in peripheral blood progenitor cell collections performed after repeated high-dose chemotherapy courses. <i>British Journal of Haematology</i> , 1997, 99, 685-691.	1.2	16
623	Conventional induction treatments do not influence overall survival in multiple myeloma. <i>British Journal of Haematology</i> , 1997, 96, 333-337.	1.2	17
624	CD3-induced T-cell activation in the bone marrow of myeloma patients: major role of CD4+ cells. <i>British Journal of Haematology</i> , 1995, 90, 625-632.	1.2	9
625	Retinoic acid inhibits the growth of human myeloma cells in vitro. <i>British Journal of Haematology</i> , 1995, 89, 555-560.	1.2	15
626	Plasma cell dyscrasias: classification, clinical and laboratory characteristics, and differential diagnosis. <i>Best Practice and Research: Clinical Haematology</i> , 1995, 8, 705-719.	1.1	24
627	Interferon- β in Multiple Myeloma. <i>Leukemia and Lymphoma</i> , 1995, 18, 215-219.	0.6	13
628	High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma. <i>Journal of Clinical Oncology</i> , 1994, 12, 503-509.	0.8	72
629	AgNORs and Myeloma Prognosis. <i>Leukemia and Lymphoma</i> , 1994, 12, 383-394.	0.6	11
630	N- and K-Ras Oncogenes in Plasma Cell Dyscrasias. <i>Leukemia and Lymphoma</i> , 1994, 15, 17-20.	0.6	28

#	ARTICLE	IF	CITATIONS
631	Recombinant interferon- β inhibits the in vitro proliferation of human myeloma cells. British Journal of Haematology, 1994, 86, 726-732.	1.2	27
632	Generation of anti-tumour activity by OKT3-stimulation in multiple myeloma: in vitro inhibition of autologous haemopoiesis. British Journal of Haematology, 1994, 87, 494-502.	1.2	5
633	Classification of patients affected by multiple myeloma using a neural network software. European Journal of Haematology, 1994, 52, 182-183.	1.1	9
634	THE MUTATION OF N-RAS ONCOGENE DOES NOT INVOLVE MYELOID AND ERYTHROID LINEAGES IN A CASE OF MULTIPLE MYELOMA. British Journal of Haematology, 1993, 83, 672-673.	1.2	3
635	Interferon plus Glucocorticoids as Intensified Maintenance Therapy Prolongs Tumor Control in Relapsed Myeloma. Acta Haematologica, 1993, 90, 71-76.	0.7	13
636	Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin (IgG)- and IgA-secreting multiple myelomas.. Journal of Experimental Medicine, 1993, 178, 1091-1096.	4.2	109
637	Multiple myeloma: "early" plasma cell phenotype identifies patients with aggressive biological and clinical characteristics. British Journal of Haematology, 1993, 85, 504-513.	1.2	29
638	Cyclosporin A and dipyridamole: An effective combination against the generation of cytotoxic T lymphocytes (CTL). Pharmacological Research, 1992, 26, 12-13.	3.1	0
639	Standard Chemotherapy for Myelomatosis: An Area of Great Controversy. Hematology/Oncology Clinics of North America, 1992, 6, 371-382.	0.9	21
640	Academic promotion in Italy. Nature, 1992, 355, 581-581.	13.7	8
641	Early disappearance of murine plasmocytoma stem cells in long-term bone marrow culture. Leukemia Research, 1992, 16, 743-750.	0.4	2
642	Multiple independent immunoglobulin class-switch recombinations occurring within the same clone in myeloma. British Journal of Haematology, 1992, 82, 676-680.	1.2	13
643	Multiple myeloma: Intensified maintenance therapy with recombinant interferon- β plus glucocorticoids. European Journal of Haematology, 1992, 49, 93-97.	1.1	9
644	Maintenance Treatment with Recombinant Interferon Alfa-2b Prolongs Remission and Survival in Patients with Multiple Myeloma Responding to Induction Chemotherapy. , 1992, , 67-72.		0
645	Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.. Journal of Clinical Oncology, 1991, 9, 444-448.	0.8	120
646	Dipyridamole <i>in vitro</i> suppresses the generation of T cell cytotoxic functions: Synergistic activity with cyclosporine. European Journal of Haematology, 1991, 46, 6-10.	1.1	2
647	Dual rearrangement of immunoglobulin and T cell receptor gene in a case of T cell hairy cell leukemia. European Journal of Haematology, 1991, 46, 71-76.	1.1	6
648	Increased serum neopterin concentration as indicator of disease severity and poor survival in multiple myeloma. European Journal of Haematology, 1991, 47, 305-309.	1.1	17

#	ARTICLE	IF	CITATIONS
649	Maintenance Treatment with Recombinant Interferon Alfa-2b in Patients with Multiple Myeloma Responding to Conventional Induction Chemotherapy. <i>New England Journal of Medicine</i> , 1990, 322, 1430-1434.	13.9	374
650	Multiple Myeloma: Beta-2-Microglobulin is not a Useful Follow-Up Parameter. <i>Acta Haematologica</i> , 1989, 82, 122-125.	0.7	18
651	Monoclonal Immunoglobulin Gene Rearrangement in Peripheral Lymphocytes of a Patient with Multiple Myeloma. <i>Tumori</i> , 1989, 75, 1-3.	0.6	4
652	Early responder myeloma: kinetic studies identify a patient subgroup characterized by very poor prognosis.. <i>Journal of Clinical Oncology</i> , 1989, 7, 119-125.	0.8	72
653	Philadelphia-positive thrombocythemia with a complex translocation involving chromosomes 9, 15, and 22. <i>Cancer Genetics and Cytogenetics</i> , 1989, 39, 77-80.	1.0	3
654	Advances in biology of multiple myeloma: Cell kinetics, molecular biology and immunology. <i>European Journal of Haematology</i> , 1989, 43, 30-34.	1.1	2
655	Human myeloma: Several subsets of circulating lymphocytes express plasma cell-associated antigens. <i>European Journal of Haematology</i> , 1988, 40, 299-304.	1.1	28
656	Lack of Correlation between Plasma Cell Thymidine Labelling Index and Serum Beta-2-Microglobulin in Monoclonal Gammopathies. <i>Acta Haematologica</i> , 1987, 78, 239-242.	0.7	17
657	Multiple Myeloma Plasma Cell Kinetics: Rapid and Reliable Evaluation using 5-Bromo-2-Deoxyuridine (BrdUrd) DNA Incorporation Detected by an Anti-BrdUrd Monoclonal Antibody. <i>Tumori</i> , 1986, 72, 135-137.	0.6	16
658	Benign monoclonal gammopathy presenting with severe renal failure. <i>Scandinavian Journal of Haematology</i> , 1986, 36, 115-117.	0.0	4
659	Reactive Plasmacytosis. <i>Acta Haematologica</i> , 1985, 73, 108-110.	0.7	20
660	Treatment of multiple myeloma: A randomized study of three different regimens. <i>Leukemia Research</i> , 1985, 9, 1043-1049.	0.4	20
661	Plasma cell acid phosphatase activity as prognostic factor in multiple myeloma: relationship to the thymidine-labeling index.. <i>Journal of Clinical Oncology</i> , 1985, 3, 1503-1507.	0.8	8
662	Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy. <i>British Journal of Haematology</i> , 1984, 58, 689-696.	1.2	91
663	Mixed lymphocyte reaction in human monoclonal gammopathies. <i>Experientia</i> , 1983, 39, 1137-1139.	1.2	0
664	Human Myeloma: Kinetics of the Remission Phase. <i>Acta Haematologica</i> , 1982, 68, 237-240.	0.7	15
665	Monitoring of a Long Survival Myeloma Patient. <i>Tumori</i> , 1981, 67, 571-573.	0.6	6
666	Early B lymphocytes in man. <i>Experientia</i> , 1980, 36, 1124-1125.	1.2	3

#	ARTICLE	IF	CITATIONS
667	Hairy-Cell Leukemia. New England Journal of Medicine, 1977, 296, 881-882.	13.9	14